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Abstract: An epidemic of chronic kidney disease (CKD) is occurring in laborers who undertake
physical work in hot conditions. Rodent data indicate that heat exposure causes kidney injury,
and when this injury is regularly repeated it can elicit CKD. Studies in humans demonstrate that a
single bout of exercise in the heat increases biomarkers of acute kidney injury (AKI). Elevations in
AKI biomarkers in this context likely reflect an increased susceptibility of the kidneys to AKI. Data
largely derived from animal models indicate that the mechanism(s) by which exercise in the heat may
increase the risk of AKI is multifactorial. For instance, heat-related reductions in renal blood flow may
provoke heterogenous intrarenal blood flow. This can promote localized ischemia, hypoxemia and
ATP depletion in renal tubular cells, which could be exacerbated by increased sodium reabsorption.
Heightened fructokinase pathway activity likely exacerbates ATP depletion occurring secondary
to intrarenal fructose production and hyperuricemia. Collectively, these responses can promote
inflammation and oxidative stress, thereby increasing the risk of AKI. Equivalent mechanistic evidence
in humans is lacking. Such an understanding could inform the development of countermeasures to
safeguard the renal health of laborers who regularly engage in physical work in hot environments.
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1. Background
An epidemic of chronic kidney disease of unknown etiology (CKDu) is occurring in laborers who
undertake physical work outdoors in hot conditions [1,2]. This disease was first described in 2002,
when nephropathy was identified in a disproportionate number of young Central American sugarcane
workers [3]. Thereafter, people in other occupations [4–6] and in other regions of the world [1,7,8] have
been diagnosed with what appears to be the same disease, although there is some heterogeneity in the
clinical signs, symptoms, and likely etiology [1,2]. The effects of CKDu are devastating. For instance,
the Pan American Health Organization estimates that CKDu caused more than 60,000 deaths in
Central America from 1997 to 2013, with 41% of these deaths occurring in people younger than 60 y
of age [9]. Furthermore, the World Health Organization estimates that ~15% of workers in endemic
areas are at risk of developing CKDu [10]. This estimate was recently corroborated in a meta-analysis
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by Flouris et al. [11]. Thus, there is an urgent need to identify effective strategies to mitigate the risk
of CKDu.
The development of countermeasures for CKDu requires an understanding of the etiology of the
disease. Unfortunately, the etiology underlying the development of CKDu is largely unknown [12].
Patients diagnosed with CKDu usually present with an asymptomatic rise in serum creatinine and
low grade proteinuria [4,5]. Renal biopsies show interstitial fibrosis, low grade inflammation, tubular
atrophy, and glomerulosclerosis with signs of ischemia [13]. The two hallmarks of CKDu are that it is
not associated with traditional risk factors of chronic kidney disease (CKD) (e.g., advanced age, diabetes,
hypertension) and that it is more common in laborers regularly exposed to hot environments [7,14–16].
There may also be a contributing role for toxin exposures (e.g., agrochemicals, heavy metals or
infectious agents) [14,17] and/or the use of agents with nephrotoxic side effects (e.g., nonsteroidal
anti-inflammatory drugs (NSAIDs)) [18,19]. However, convincing evidence supporting these factors as
being primary in the etiology of CKDu is lacking [2,20,21]. Thus, it has been suggested that heat may be
the key occupational exposure contributing to the development of CKDu [7,14,22]. This is supported
by data indicating a higher prevalence of CKDu in agriculture workers exposed to hotter climates
compared to those working in cooler climates, despite otherwise enduring the same occupational
conditions [4,6]. As a result, it has been proposed that CKDu is a form of ‘heat stress nephropathy’,
the risk of which could worsen with climate change [7,16,23]. That said, it is important to note that
while factors associated with engaging in physical work in the heat are likely to play an important role,
the etiology of CKDu is mostly unknown and may be multifaceted [7,24,25].
One leading etiological hypothesis for CKDu is that physical work (i.e., exercise) in the
heat, which leads to heat strain (i.e., increased core body temperature) and dehydration (i.e., a
hypovolemic–hyperosmotic state caused by the loss of body water due to sweating combined with
inadequate fluid intake), causes acute kidney injury (AKI) [2,7,15,16,26–28]. This heat-related AKI is
probably transient in nature [29–32], which is clinically defined as lasting <3 days [33]. Nevertheless, it
has been proposed that multiple transient AKI exposures can manifest as nephropathy, affecting the
renal tubules and glomeruli [7,15,16,27].
Subclinical rhabdomyolysis (i.e., muscle injury), which may occur during (or after) unaccustomed
intense or prolonged exercise [34], is often proposed to contribute to heat-related AKI and
CKDu [7,14,35]. This is supported by human data demonstrating that the presence of muscle damage
increases the risk of AKI during exercise in the heat [36]. These data were recently corroborated in
a rodent model of repeated heat exposure, which demonstrated that experimental rhabdomyolysis
worsened heat-induced kidney injury [37]. That said, epidemiological data obtained from Guatemalan
sugarcane workers indicate that the presence of rhabdomyolysis is not associated with cross-shift
declines in kidney function [26], suggesting that the contribution of rhabdomyolysis to progressive
reductions in kidney function in this population is likely small. This can be explained by the adaptation
of skeletal muscle to become more resistant to damage after the initial injurious exercise [38]. Thus,
while the first few days of unaccustomed intense physical work in the heat may induce subclinical
rhabdomyolysis, the subsequent muscle damage incurred by manual laborers on a daily basis is
probably small. Therefore, the contribution of subclinical rhabdomyolysis to heat-related AKI and
CKDu is likely minimal.
It is important to note that there is currently no direct support for recurrent heat-related AKI
in the etiology of CKDu [39]. For instance, to our knowledge a dose–response relation between
the frequency and severity of heat-related AKI and the subsequent development of CKD has
never been experimentally examined in rodent models nor explored in epidemiological studies.
That said, in the absence of heat exposure, data from pre-clinical models indicate that AKI can
result in renal tubular remodeling [40,41], which can lead to long-term impairments in kidney
function, the defining characteristic of CKD [40,42–46]. More recently, these findings have been
extended to instances of combined heat exposure and dehydration. For instance, rodents develop
nephropathy with intermittent, repeated passive (i.e., resting) heat exposure without access to fluids
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over 4–5 weeks [47–49]. Importantly, these animals demonstrate evidence of kidney injury, which is
consistent with the recurrent heat-related AKI hypothesis [47–49]. These data are corroborated by
workplace data demonstrating increases in biomarkers of AKI both across a work shift and across the
harvest season [31,32,50–55]. Notably, the working conditions during these periods are conducive
to increased heat strain, dehydration, and reductions in kidney function [31,32,50–55]. Whether the
observed increases in AKI biomarkers translate to an increased risk of CKD is unclear [56]. That
said, epidemiological evidence clearly indicates that the frequency and severity of non-heat-related
AKI is associated with the incidence and severity of CKD [57–61]. For instance, a single episode of
relatively mild (Stage 1) AKI results in a 43% increased risk of developing advanced stage CKD within
one year [57]. Furthermore, even a single episode of transient AKI that lasted ≤2 days is associated
with a ~2-fold increased risk of death [62] and a 1.4-fold increased risk of developing CKD [57].
Thus, it is generally accepted that an increased frequency, severity, and/or duration of AKI elevates
the risk of developing CKD [63,64], although this remains a topic of debate that requires additional
exploration [44,63–65]. Against this background, the etiology of CKDu may be better understood by
investigating the pathophysiology of the increased risk of AKI in humans exercising in the heat. This
latter point is particularly important. For instance, experimentally manipulating CKDu risk in humans
is unethical. However, quantification of the risk of AKI in humans may be readily accomplished
when studies are carefully designed to ensure the risk of AKI is short lasting and completely resolved
between experimental periods.
Despite the proposed relation between heat exposure and CKDu, the effects of heat strain and
dehydration elicited by exercise in the heat on kidney health and the risk of AKI in humans is
largely unexplored. We believe that this is likely because changes in kidney function induced by
heat strain, exercise, and/or dehydration are believed to be physiological in nature, clinically benign,
and completely reversed with recovery [17]. Emerging evidence, however, calls this dogma into
question [2,14,16,36,47,51,54,66–70]. Therefore, the purpose of this narrative review is to present
evidence that exercise in the heat may increase the risk of developing AKI in humans. In doing so,
we will also address how the risk of AKI can be examined in humans and we will discuss some of
the potential mechanisms underlying this risk. A focus will be placed on human subjects research,
but data from non-human animals will be included where necessary. Several important knowledge
gaps will also be presented. Filling these knowledge voids is vital to identifying strategies to mitigate
the risk of AKI and CKDu in workers who regularly engage in physical work in hot environments.
2. Acute Kidney Injury
AKI refers to a clinical condition characterized by a rapid (i.e., occurring within ≤7 days) reduction
in kidney function [71]. AKI can be further categorized as transient (i.e., lasting <3 days) or sustained
(i.e., lasting ≥ 3 days) [33]. AKI is often reversible, but can be fatal both in the acute setting and
in relation to an increased risk of CKD, which is defined as a gradual loss of kidney function that
persists for >90 days [72]. Clinically, the presence and the severity of AKI is diagnosed via criteria
established by international working groups such as the Acute Kidney Injury Network (AKIN) [73],
the Acute Dialysis Quality Initiative (ADQI) [74], and Kidney Disease: Improving Global Outcomes
(KDIGO) [71,75], amongst others. The criteria for identifying and categorizing the severity AKI differs
slightly between these working groups. However, the common denominator for classifying AKI among
these working groups is an acute reduction in kidney function. Changes in kidney function are often
quantified via changes in glomerular filtration rate (GFR), which is widely accepted as the best overall
index of kidney function in both health and disease [71], and the rate of urine production (aka: urine
flow rate). Precise measurements of GFR can be cumbersome, impractical and/or costly. Thus, GFR is
often estimated from the clearance of endogenous creatinine from the circulation [76]. Creatinine is
formed from muscle creatine and released into the blood at a relatively constant rate provided there are
no changes in muscle mass or muscle damage during the period of observation. Importantly, creatinine
is not reabsorbed along the nephron tubule lumen. Correcting urinary creatinine excretion rate for
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serum creatinine (a systemic variable that could also influence urinary creatinine excretion) provides
an accurate measure of GFR [76]. Thus, creatinine clearance is a function of urine flow rate and serum
and urinary creatinine concentrations at any given time and can be calculated as:
GFR ≈ Clearance Creatinine =
[Creatinine]urine ×Urine f low rate
[Creatinine]serum
where: GFR is glomerular filtration rate, ClearanceCreatinine is creatinine clearance, [Creatinine]urine is the
urinary concentration of creatinine, Urine flow rate is the volume of urine produced per unit time, and
[Creatinine]serum is the serum concentration of creatinine.
Precise assessment of urine flow rate can be difficult in ambulatory or free-living settings. Therefore,
GFR is often further estimated based upon serum creatinine and equations incorporating corrections
for age, sex, race and body size, thereby eliminating the need for urine collection [76]. As a result, a
spot assessment of serum creatinine is often part of routine medical practice for assessment of kidney
function [77]. It is also important to note that there is growing support for a spot assessment of
circulating cystatin C as a marker of kidney function [78]. Cystatin C is produced at a stable rate by all
cells within the body and freely filtered by the glomeruli. The potential benefit of using cystatin C is
that changes in cystatin C during dynamic fluctuations in kidney function may occur much earlier than
changes in serum creatinine [79]. In theory, this could provide for more rapid diagnoses of AKI [78].
Importantly, to our knowledge, cystatin C has never been used to quantify kidney function during
exercise in the heat. Moreover, despite evidence that cystatin C may provide useful information,
the clinical practice guidelines for the diagnosis and classification of the severity of AKI are currently
based on acute changes in serum creatinine and/or absolute urine flow rate (Table 1).
The underlying basis for the AKI guidelines is the relation between serum creatinine and kidney
function, and that rapid decreases in kidney function define AKI. A limitation regarding the use of
changes in kidney function as diagnostic criteria for AKI (whether quantified via changes in serum
creatinine, urine flow rate, or cystatin C), is that GFR is often acutely reduced as a result of an integrated
physiological response (i.e., conditions extrinsic to the kidneys). This is often referred to as prerenal
AKI [80], whereby increases in serum creatinine (and/or reductions in urine flow rate) may satisfy
the definition of AKI, but these reductions in kidney function are due to neural, hormonal, and/or
hemodynamic responses upstream of the kidneys. For example, GFR and urine flow rate are decreased
during dehydration [81,82]. This is likely due to reductions in renal blood flow [83,84] caused by
increases in renal sympathetic nerve activity [85,86], vasopressin release [87], and activation of the
renin–angiotensin–aldosterone system [88]. These are normal and healthy physiological responses that
promote fluid conservation [89]. Thus, increases in serum creatinine, which are normally reflective of a
reduction in GFR, may not always be indicative of kidney injury during dehydration [80]. Because of
this, it is often recommended that the creatinine and/or urine flow rate-based diagnostic criteria for
AKI be used only after an optimal state of hydration has been achieved [73]. However, an optimal
hydration state is ill-defined given that no single variable truly captures body fluid status [90].
Given the limitations of kidney function-derived AKI diagnoses, a rapidly growing body of
literature aiming to identify biomarkers of AKI has emerged [91]. The goal of these biomarkers is
to identify those individuals at risk of developing AKI before any reductions in kidney function
occur [92–95]. It has recently been reported that over the past 10 years there have been 3300 scientific
publications and hundreds of AKI biomarkers investigated [91]. The validity and clinical utility of
many of these biomarkers remains to be determined, even for well-studied AKI biomarkers [91,96].
However, when combined with standard indices of kidney function, measurement of AKI biomarkers
may provide unique information regarding interactions between changes in kidney function and
the potential for AKI [96,97]. In the following, we will introduce a few promising AKI biomarkers,
with an emphasis on those that have been used in experimental human subjects research, particularly
as it relates to exercise, dehydration, and/or heat strain, or that demonstrate potential for use in
laboratory-based (i.e., not clinical settings) human subjects studies. An in-depth overview of AKI
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biomarkers is outside of the scope of this review. Thus, to the interested reader we recommend a number
of more comprehensive reviews addressing the pathophysiological bases and clinical performance of
AKI biomarkers [92–95].
Table 1. Clinical criteria for identifying acute kidney injury and staging the severity of injury.
Criteria
Serum Creatinine Urine Output
Acute Kidney Injury Network (AKIN) Classification
Stage 1 Increase ≥0.3 mg/dL (≥26.5 µmol/L) OR increase≥1.5–2.0-fold from baseline <0.5 mL/kg/h for 6 h
Stage 2 Increase >2.0–3.0-fold from baseline <0.5 mL/kg/h for 12 h
Stage 3
Increase >3.0-fold from baseline OR serum creatinine
≥4.0 mg/dL (≥354 µmol/L) with an acute increase of
≥0.5 mg/dL (44 µmol/L) OR need for renal
replacement therapy
<0.3 mL/kg/h for 24 h OR anuria for 12 h
OR need for renal replacement therapy
Kidney Disease: Improving Global Outcomes (KDIGO) Classification
Stage 1 Increase ≥0.3 mg/dL (≥26.5 µmol/L) OR 1.5–1.9times baseline <0.5 mL/kg/h for 6-12 h
Stage 2 2.0–2.9 times baseline <0.5 mL/kg/h for 12 h
Stage 3
3.0 times baseline OR increase in serum creatinine to
≥4.0 mg/dL (≥354 µmol/L) OR need for renal
replacement therapy OR in patients <18 years old a
decrease in eGFR to <35 mL/min/1.73 m2
<0.3 mL/kg/h for 24 h OR anuria for 12 h
Acute Dialysis Quality Initiative (ADQI):
Risk, Injury, Failure, Loss of Kidney Function and End-Stage Kidney Disease (RIFLE) Classification
Risk 1.5-fold increase OR GFR decrease >25%from baseline <0.5 mL/kg/h for 6-12 h
Injury 2.0-fold increase OR GFR decrease >50%from baseline <0.5 mL/kg/h for 12 h
Failure
3.0-fold increase OR GFR decrease >75% from
baseline OR serum creatinine ≥4.0 mg/dL
(≥354 µmol/L) with an acute increase of ≥0.5 mg/dL
(44 µmol/L)
<0.3 mL/gk/h for 24 h OR anuria for 12 h
Loss of kidney
function Complete loss of kidney function >4 weeks
End-stage
kidney disease Complete loss of kidney function >3 months
Abbreviations: GFR: glomerular filtration rate, eGFR: estimated glomerular filtration rate. Please refer to text
for references.
AKI Biomarkers
Neutrophil gelatinase-associated lipocalin (NGAL) is expressed in multiple cell types (e.g., renal,
hepatic, cardiac, etc.) at relatively low, but constant levels [98]. NGAL generally functions as a
bacteriostatic agent [99]. Urinary NGAL is the most widely studied biomarker of AKI [94]. Renal
NGAL mRNA and protein are strongly upregulated after ischemic or toxic kidney injury in both
human and animal models [100–103]. In the kidneys, NGAL is produced in the thick ascending limb
of the loop of Henle and intercalated cells of the collecting duct [104]. In addition, circulating NGAL
from extrarenal sources is filtered by the glomeruli and reabsorbed in the proximal tubules [105].
The increased urinary NGAL concentrations in the context of AKI are likely caused by endogenous
NGAL production in the kidneys and reductions in tubular NGAL reabsorption [94,104], a hypothesis
supported by clinical evidence that urinary NGAL is not elevated in isolated prerenal AKI [33,106],
although these findings are not unanimous [107]. Therefore, urinary NGAL appears to be a marker
of general tubular injury, without a specific etiology [93,94,104] (Figure 1). Plasma NGAL may also
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have some utility as a biomarker of AKI [93]. However, increases in plasma NGAL likely more readily
reflect reductions in GFR, as well as renal ischemia and/or glomerular dysfunction [93,95] (Figure 1).Nutrients 2019, 11, x FOR PEER REVIEW 7 of 25 
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injury (AKI) and common clinically relevant measures indicative of overall kidney function. Bottom:
Potential etiology underlying increases in AKI biomarkers. Abbreviations—NGAL: Neutrophil
gelatinase-associated lipocalin, [IGFBP7•TIMP-2]: the product of Insulin-like growth factor binding
protein 7 (IGFBP7) and tissue inhibitor metalloproteinase 2 (TIMP-2), KIM-1: Kidney injury molecule-1,
L-FABP: Liver-type fatty acid binding protein, IL-18: Interleukin-18. Please refer to text for references.
Kidney injury molecule-1 (KIM-1) is a transmembrane glycoprotein that is expressed at low levels
in the normal kidney, but is further upregulated following ischemia-reperfusion and toxic kidney
injury [108,109]. KIM-1 is mainly upregulated in proximal tubule cells during AKI [110,111]. Thus,
increases in urinary KIM-1 likely indicate proximal tubule injury, although the etiology is nons ecific
(Figure 1). Clinical studies nvestiga ing the utility of KIM-1 have shown variable results [94].
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Liver-type fatty acid binding protein (L-FABP) is a cytoplasmic protein that protects against oxidative
stress induced by peroxisomal metabolism [112], particularly in the presence of hypoxia given that the
human L-FABP gene contains a hypoxia-inducible factor 1α response element [113]. L-FABP is excreted
by proximal tubule epithelia into the tubular lumen together with bound peroxisomal products [113].
Urinary L-FABP can likely be used to identify patients at risk of developing AKI. This is supported
by data indicating that patients with high L-FABP levels measured at the time of intensive care unit
admission had a greater risk for developing AKI within 1 week, compared to a group of patients
with lower L-FABP levels [114]. The genetic link with hypoxia-inducible factor 1α, together with
findings indicating that urinary L-FABP levels are strongly correlated with the duration of ischemia
in kidney transplant recipients [113], suggests that urinary L-FABP may provide an indication that
the mechanism of this risk of AKI is related to proximal tubule hypoxemia and the development of
oxidative stress (Figure 1).
Interleukin-18 (IL-18) is a proinflammatory cytokine that is produced in the intercalated cells of the
collecting ducts of healthy kidneys [115], but is more broadly made in tubular epithelial cells as part
of the inflammatory cascade induced by AKI [116]. Urinary IL-18 has been shown to be a promising
biomarker of AKI in animal models [94]. Clinical studies also demonstrate that urinary IL-18 may have
utility in predicting AKI [117]. However, its diagnostic value remains less clear [117]. Nevertheless,
urinary IL-18 is likely a marker of general tubular injury and subsequent inflammatory-pathway
activation (Figure 1).
Insulin-like growth factor binding protein 7 (IGFBP7) and tissue inhibitor metalloproteinase 2 (TIMP-2)
are proteins known to induce G1 cell cycle arrest [118]. In general, cell cycle arrest likely occurs to
prevent potential DNA damage during cellular stress [119]. However, if cells stay in a phase too long or
exit a phase too soon, the normal division and repair process can become maladaptive [120]. Cell cycle
arrest occurs in renal epithelial cells in a variety of in vitro models of AKI [121] and is associated with
the development of fibrosis following multiple types of AKI in rodents [122]. The arithmetic product
of urinary IGFBP7 and urinary TIMP-2 ([IGFBP7•TIMP-2]) was identified as an AKI biomarker in a
clinical study in which it outperformed ~338 other candidate biomarkers at predicting AKI based on
standard clinical criteria (Table 1) [123]. In 2014, an [IGFBP7•TIMP-2] test system (better known by
its proprietary name, NEPHROCHECK®) received FDA approval for marketing as a screening tool
to estimate the risk of AKI development [124]. FDA approval carefully stipulated that increases in
[IGFBP7•TIMP-2] should not necessarily be interpreted to indicate that AKI is ongoing. This indication
is consistent with the fact that G1 cell cycle arrest occurs during the very early stages of cellular
stress [125]. Notably, [IGFBP7•TIMP-2] is the only biomarker approved by the FDA for an AKI related
indication [124]. Recent evidence indicates that increases in urinary [IGFBP7•TIMP-2] following
diverse forms AKI is contributed to by a multitude of factors, which include decreases in glomerular
permeability, proximal tubular cell leakage, and impaired reabsorption of IGFBP7 and TIMP-2 in
the proximal tubule [126]. Thus, increases in [IGFBP7•TIMP-2] can be interpreted as evidence of
the potential for renal injury of a nonspecific origin occurring in the glomeruli and proximal tubules
(Figure 1).
3. Interpretation of AKI Biomarkers in Non-Clinical Settings
Recent advances in our understanding of AKI biomarkers have unexpectedly resulted in reports
of the potential for AKI in situations traditionally considered to be clinically benign for the kidneys.
This is highlighted by studies consistently demonstrating increases in AKI biomarkers following a
single bout of prolonged endurance exercise [127–132]. Such findings have raised the question as
to whether regularly engaging in endurance exercise may lead to poor renal health outcomes [133].
Arguments against this position are numerous and highlighted by the supposition that since the
development of the ‘jogging phenomenon’ in the early 1960s [134] there has not been a profound
increase in the incidence of AKI. Rather, the epidemic of AKI in the general population is largely
attributed to patients hospitalized with acute illnesses and those undergoing major surgery, which may
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be partially contributed to by a greater recognition of AKI, and improved diagnostic and classification
criteria [135]. Moreover, regularly engaging in vigorous physical activity (such as endurance exercise)
reduces the risk of developing CKD [136], suggesting that the repeated exposures to exercise-induced
elevations in AKI biomarkers does not lead to long-term sequelae. This has raised the question
regarding how to interpret acute increases in AKI biomarkers in otherwise healthy individuals. This is
an important consideration with regards to understanding the risk of AKI occurring subsequent to
exercise in the heat.
The AKI biomarkers described herein were developed to identify AKI as would occur in clinical
situations, in which large and sustained elevations were expected. In such instances, elevations in
these AKI biomarkers would be indicative of intrinsic renal damage occurring at various locations
along the nephron (Figure 1) [96,137]. Data obtained from otherwise healthy individuals engaging
in endurance exercise demonstrate consistent increases in AKI biomarkers [127–132], but these
elevations are often shorter in duration and not to the same extent as those observed in clinical
situations [100–103,113,117,123]. These consistent elevations in AKI biomarkers are often interpreted
as meaningful, but because the increases are small, they are usually not interpreted as being indicative
of intrinsic renal injury. Rather, these small increases in AKI biomarkers likely reflect an increased
potential to develop of AKI, although the possibility that increases in AKI biomarkers reflect some
degree of intrinsic injury cannot be completely ruled out at this time. We believe this conclusion is
indirectly supported by evidence that elevations in AKI biomarkers in the laboratory setting typically
resolve ~24 h following exercise [127,130]. Thus, small, transient increases in AKI biomarkers are
likely indicative of acute kidney stress [138]. This state likely represents a period in which there
is an increased risk of developing AKI, with the magnitude of this risk occurring in proportion
to the magnitude of elevations in AKI biomarkers. Notably, this definition is consistent with the
FDA approved indication for urinary [IGFBP7•TIMP-2] as a biomarker of the magnitude of the risk
associated with developing AKI.
Currently, there is no consensus regarding the best AKI biomarker to measure. Urinary NGAL
may have the most robust evidence base [94], but only urinary [IGFBP7•TIMP-2] has an FDA approved
indication for AKI [124]. That said, to our knowledge no study has measured urinary [IGFBP7•TIMP-2]
under conditions of exercise, heat strain and/or exercise. In this context, there is likely value in
employing a battery of assays for AKI biomarkers. This approach may provide important insights
regarding: (i) the magnitude of the risk of AKI, (ii) the anatomical location where this risk originated,
and (iii) the potential etiology of this risk (Figure 1). Such an understanding may provide important
information towards determining countermeasures to reduce the risk of AKI in the context of exercise
in the heat.
There is likely also value in combining the measurement of AKI biomarkers with traditional
indices of kidney function (e.g., serum creatinine, urine flow rate, etc.) for interpreting the risk of
AKI. This approach has been proposed in the clinical literature as a method to discern prerenal AKI
(i.e., only a reduction in kidney function without increases in AKI biomarkers) from intrinsic AKI
(i.e., a reduction in kidney function with increased AKI biomarkers) or subclinical AKI (i.e., increased
biomarkers in the absence of a reduction in kidney function) [96,97,137,139]. In a similar manner,
the risk of AKI can likely be assessed in the context of exercise in the heat (Figure 2). For instance,
a decrease in kidney function without increases in AKI biomarkers may be indicative of a relatively
mild risk for AKI because the change in function is unlikely to be pathological. This decline in kidney
function may be the normal physiological response of the kidneys to a stressor (such as exercise) that
is completely reversed once the stress has abated. That said, increases in AKI biomarkers without a
change in kidney function may be interpreted as a slightly higher (i.e., moderate) risk of AKI, owing
to the presence of potential pathological processes. Finally, the highest risk of AKI may occur when
kidney function is reduced alongside increases in AKI biomarkers. Moreover, this risk could be further
delineated based on the magnitude of the reductions in kidney function and/or increases in AKI
biomarkers. For example, the condition invoking the greatest reductions in kidney function and largest
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increases in AKI biomarkers would be interpreted as having the highest risk of AKI. Notably, however,
this AKI risk matrix is likely only useful in situations where comparisons between conditions might be
considered the most important (i.e., it may only provide an index of relative AKI risk). The utility of
this matrix for providing information regarding absolute AKI risk is currently unclear.
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Fina ly, an important method logical onsideration is the normalization of urinary AKI biomarkers
t urine concentration. It is common in clinical and research settings to correct urine-based AKI
biomarkers by no malizing to urinary creatinine [140]. However, the application of urinary reatinine
normalizatio in exe cise models is likely flawe [36]. This is because urinary creatinine excretion
b comes inconsistent both withi and between subjects during and following exercise, owing to
relat vely large swings in GFR [141]. Thus, in controlled laboratory settings it is often suggested hat
th most accurate me od t quantify renal bi markers requi s the c llection of timed urine specime s
to estimate the excretio rate of a giv n bioma ker [140]. Therefor , concent ations of urinary AKI
biomarkers in the context of exercise in the heat are often normalized o urine flow rate [30,36]. That
said, normalization to other markers f urinary concentration (e.g., osmolalit ) may also be a valid
approach [131,132].
4. AKI Susceptibility Evoked by Exercise in the Heat in Humans
Clinical AKI associated with exercise in the heat has occasionally been reported in the clinical
literature. To our knowledge, the most complete clinical dataset was published in 1967, which reported
the cases of eight previously healthy military recruits who had developed AKI during training exercises
outdoors in the summer months [142]. The overall incidence of AKI is generally very low in this
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population of military recruits. However, it was later estimated that ~10% of the AKI cases treated at
Walter Reed General (Military) Hospital from 1960 to 1966 were due to AKI occurring subsequent to
exercise in the heat [143]. Thus, there is clinical evidence that exercise in the heat can bring about AKI,
at least in a subset of individuals.
More recently, traditional measures of kidney function have been combined with AKI biomarkers
to examine the risk of AKI during exercise in the heat. Generally, the findings from these studies
suggest that exercise in the heat can increase the susceptibility to AKI. For instance, Junglee et al.
demonstrated that mild heat strain (+1.3 ◦C increase in core temperature) and mild dehydration (~1%
body weight loss) due to exercise in the heat resulted in elevations in serum creatinine, reductions
in urine flow rate, and increases in plasma NGAL [36]. Our laboratory has furthered this work and
found that elevations in serum creatinine and plasma NGAL were influenced by the magnitude of
increases in core temperature and the extent of dehydration produced by exercise in the heat of two
different durations [29] (Figure 3). Of the increases in serum creatinine, ~30% of the observations
satisfied the criteria for stage 1 AKI according to the AKIN criteria (Table 1) [73] (Figure 3). We
also showed that elevations in serum creatinine and plasma NGAL returned to baseline levels the
following day [29] (Figure 3), which is supportive of the idea that this period of an increased risk
of AKI is transient. Similarly, McDermott et al. found that 4–6 h of exercise in the heat, which
evoked moderate dehydration (~1.6% body weight loss), elevated both serum creatinine and serum
NGAL [70]. Collectively, the findings to date support that exercise in the heat can increase the risk
of AKI in humans and that this increased risk occurs in proportion to the magnitude of heat strain
and dehydration. To our knowledge, however, no study in the context of exercise in the heat has
systematically examined markers of kidney function simultaneous with a panel of AKI biomarkers.
This is a significant limitation with regards to the strength of the evidence base. Thus, future studies
are necessary to conclusively determine the risk of AKI caused by exercise in the heat.
Importantly, many of the potential modulators of the magnitude of AKI risk evoked by exercise in
the heat remain largely unexplored. This is important because resolving these unknowns will have
important ramifications regarding the development of countermeasures to alleviate the risk of AKI
during exercise in the heat. For instance, the relative importance of heat strain versus dehydration on
the magnitude of the risk of AKI evoked by exercise in the heat is unknown. Although a formal body
of evidence is lacking, there is evidence that hydration status may be a comparatively more important
modulator of AKI risk compared to heat strain alone. For instance, allowing rodents full access to
water during 4 weeks of repeated heat exposure prevented the renal injury and nephropathy that
occurred in the rodents that were exposed to the same heat load, but were restricted from drinking
during the heat exposures [47]. Thus, it can be speculated that hydration status is the most important
modulator of AKI risk during exercise in the heat. That said, a limitation of this conclusion is that
core temperature is often elevated to a greater extent in a dehydrated state during exercise and/or
heat exposure [144]. In the aforementioned study, core temperature in the rats was not measured [47].
Therefore, the comparative importance of heat strain versus dehydration on the risk of AKI during
exercise in the heat remains largely uncertain. Another important knowledge gap is the effect of
substances that have nephrotoxic side effects on the risk of AKI during exercise in the heat. The best
example is likely NSAIDs, which are commonly used in occupational settings [18,19]. Notably, a
1.2 g dose of the NSAID ibuprofen results in greater reductions in GFR during exercise in the heat
compared to a placebo condition [145]. However, recent evidence indicates that this deleterious effect
on kidney function does not translate to a greater risk of AKI, such that a 0.6 g dose of ibuprofen did
not lead to greater increases in serum NGAL following 4–6 h of exercise in the heat [70]. However,
these findings may be explained by the lower NSAID dose (0.6 vs. 1.2 g). Thus, future studies are
required to elucidate the modulatory role of nephrotoxic substances (particularly NSAIDs) on the risk
of AKI during exercise in the heat.
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(A) and dehydration (B) resulted in greater changes (∆) in serum creatinine (C), which were sufficient
to satisfy the criteria for Stage 1 acute kidney injury (AKI) in ~30% of the subjects (D), and greater
increases in plasma neutrophil gelatinase-associated lipocalin (NGAL) (E). * different from SHORT
(p < 0.05), Mean ± SD, n = 29. From Schlader et al. [29] with permission.
Mechanisms of AKI Susceptibility Evoked by Exercise in the Heat
In general, the mechanisms by which exercise in the heat may increase the risk of AKI in humans
remain largely unexplored. That said, data from animal models, together with some fundamental
physiological data in humans, suggest that the potential increased risk of AKI provoked by exercise in
the heat is multifactorial.
Heat strain [145,146], dehydration [81,82] and exercise [147–149] independently reduce renal blood
flow in humans, and even more profound reductions in perfusion are observed when these conditions
are combined [150]. These reductions in renal perfusion are largely due to increases in renal sympathetic
nerve activity [151] and circulating vasopressin levels [152], but may also be contributed to by activation
of the renin–angiotensin–aldosterone system. For instance, angiotensin II has vasoconstrictor actions
in the kidneys [153] and may modulate kidney function during exercise in the heat in humans [154].
Notably, these declines in renal perfusion typically resolve with recovery [36,145,146,150] and are
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generally considered to be clinically inconsequential [16]. That said, data from dehydrated rats
indicate that reductions in overall renal perfusion can invoke a heterogenous distribution of blood
flow within the kidneys [84]. Strikingly, in this same study a sub-analysis of data from one rat
using a different experimental technique indicated that dehydration can produce localized ischemia,
particularly in cortical regions [84]. These data are seemingly corroborated by data in dogs whereby
heat strain-induced reductions in renal perfusion were solely caused by reductions in cortical blood flow,
without a change in medullary blood flow [155]. This relatively low blood flow state can compromise
oxygen delivery to the renal cortex, which could provoke ischemia and a localized reduction in ATP [84].
Importantly, a low ATP environment can theoretically increase the risk of AKI secondary to increased
oxidative stress and inflammation [156].
Against this background, it is clearly important to understand how exercise in the heat may affect
renal vascular control in humans, particularly as it relates to intrarenal blood flow distribution and
oxygenation. To our knowledge, such studies have never been carried out. This knowledge gap may be
important for understanding the mechanisms by which exercise in the heat may increase the risk of AKI.
For instance, the renal cortex, which demonstrates reductions in blood flow during dehydration (in
rats) [84] and heat strain (in dogs) [155], anatomically houses the majority of the proximal tubules [157],
where upwards to 65% of sodium is reabsorbed [158]. Sodium reabsorption in the kidneys can be
directly stimulated by aldosterone [159], angiotensin II [160] and/or increases in renal sympathetic
nerve activity [161], all of which are increased with heat strain, dehydration and/or exercise in an effort
to maintain fluid homeostasis [162–164]. Sodium reabsorption is energetically expensive, owing to the
reliance on the Na+/K+ pump [165]. Thus, an increased demand for sodium reabsorption may increase
the susceptibility of the kidneys to injury particularly in the presence of additional stressors that can
compromise ATP production (e.g., low blood flow). This is supported by data demonstrating that
blocking the actions of aldosterone via the administration of a mineralocorticoid receptor antagonist
attenuates the severity of injury in a rat model of mild ischemia-induced AKI [166], and prevents
the subsequent development of CKD in a similar rodent model of ischemic AKI [167]. Aldosterone
exerts its sodium reabsorption actions via the Na+/K+ pump [159]. Thus, these data support the idea
that increased energy demands associated with activation of the Na+/K+ pump can contribute to the
incidence and severity of AKI. Whether this holds true in the context of exercise in the heat remains
unknown. Notably, sodium reabsorption is greater during exercise in the heat compared to passive heat
exposure to the same extent of dehydration and heat strain [164], suggesting that exercise in the heat
evokes a relatively large renal ATP demand. Moreover, sodium reabsorption is greater during exercise
in the heat in the presence of dehydration [168]. This increased ATP demand is further challenged
by the relatively low renal cortical oxygen delivery that is likely occurring subsequent to heat strain,
dehydration and exercise. Oxygen delivery is required to sustain ATP production. Moreover, any
mismatch between oxygen delivery and oxygen demand increases the susceptibility of the kidneys
to injury [169], which likely occurs subsequent to increased oxidative stress and inflammation [156].
Thus, it is possible that a redistribution of blood flow within the kidneys, together with an increased
oxygen demand, contributes to the increased risk of AKI during exercise in the heat. However, direct
evidence is warranted.
There is certainly reason to believe that reductions in renal blood flow contribute to the increased
risk of AKI during exercise in the heat in humans. However, there are two arguments against
this contention. First, heat acclimation (or acclimatization) invoked by repeated heat exposures
stimulates greater reductions in renal blood flow during heat exposure in rats [170], which contributes
to improvements in heat tolerance [171]. Recent evidence, however, indicates that heat acclimation
over a 23 day period attenuated the rise in serum creatinine during exercise in the heat in humans [172].
This was interpreted as evidence that heat acclimation likely has a protective effect in the kidneys,
such that the incidence of serum creatinine defined AKI was attenuated with heat acclimation [172].
Despite the limitations associated with using serum creatinine to define AKI risk, such findings suggest
that the presumed greater reductions in renal blood flow during exercise in the heat following heat
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acclimation may not translate to a greater risk of AKI. That said, it is important to note that workers
experiencing CKDu are likely heat acclimated. Thus, the presumed protective effect of heat acclimation
on kidney health remains uncertain. Second, older adults have attenuated reductions in renal blood
flow during exercise in the heat [173] and passive heat exposure [174]. However, the incidence of AKI
during heat waves is disproportionately higher in older adults compared to younger adults [175–178].
Thus, the theoretical benefit conferred by the relative maintenance of renal blood flow during heat
exposure may not be protective against the risk of AKI in older adults. That said, these findings
may be confounded by other age-related changes in kidney function, such as overactivation of the
polyol-fructokinase pathway [179] and augmented vasopressin responses [180,181], both of which are
discussed below. Nonetheless, there is a clear need to discern the role of reductions in renal blood flow
to the increased risk of AKI during exercise in the heat in humans.
Rodent models also convincingly demonstrate that nephropathy due to recurrent AKI elicited by
repeated heat exposures is contributed to by activation of the intrarenal polyol-fructokinase pathway
and the endogenous production of fructose [47–49,182,183]. The polyol pathway is stimulated by an
increased plasma osmolality that upregulates the enzyme aldose reductase [184]. Aldose reductase
catalyzes the conversion of glucose into sorbitol, which has a protective effect against a hyperosmolar
renal environment [184]. However, this benefit is not sustainable. Recent evidence has uncovered
the potential deleterious effect of the subsequent activation of the fructokinase pathway, particularly
with recurrent heat exposure and/or dehydration [185]. Under such conditions, sorbitol can be
metabolized to fructose by sorbitol dehydrogenase and this fructose is then broken down by the
enzyme fructokinase [185]. The metabolic breakdown of fructose occurs rapidly and is energetically
costly [186]. Thus, activation of the fructokinase pathway can further reduce ATP availability [187].
It should be noted that the anatomical location of the polyol-fructokinase pathway is the proximal
tubules [185,186], a location that likely has experienced a selective reduction in blood flow [84,155]
and probably already has a heightened ATP demand [165] due to sodium reabsorption [164,168]
and the activation of the Na+/K+ pump [159]. Collectively, this reduced ability to generate ATP
can promote oxidative stress and inflammation [156] and can stimulate uric acid production [186].
Notably, hyperuricemia can further reduce renal perfusion [188] and independently can incite the
polyol-fructokinase pathway [49,189], thereby exacerbating the oxidative stress and inflammation [67]
that ultimately causes AKI [156]. Importantly, the fructokinase pathway is at least partially mediated
by actions associated with vasopressin release [48,183,190], the production of which is stimulated by
increases in plasma osmolality and/or hypovolemia [191].
The importance of the polyol-fructokinase pathway in AKI associated with heat exposure is
highlighted by data indicating that when rats consume a high fructose beverage, which exogenously
increases substrate for the fructokinase pathway, the resulting AKI and kidney damage from recurrent
heat exposure is exacerbated [182,183]. Moreover, when the ability to generate fructokinase is genetically
knocked out, mice exposed to recurrent heat exposure do not demonstrate AKI or kidney damage [47].
We have recently provided similar evidence in humans such that drinking a soft drink with a high
fructose content during and following 4 h of exercise in the heat exacerbates increases in serum
creatinine, reductions in urine flow rate, and elevations urinary NGAL, compared to when drinking
an equivalent amount of water [30] (Figure 4). Interestingly, this observation occurred alongside
greater increases in copeptin (a stable surrogate for vasopressin) and serum uric acid (Figure 4). These
latter findings support the animal data [48,182,183] and the mechanisms by which the activation of
the polyol-fructokinase pathway may increase the risk of AKI [185]. This recent work suggests that
polyol-fructokinase pathway activity may modulate kidney function and the risk of AKI following a
single bout of exercise in the heat in humans. It is important to note, however, that to our knowledge
there is no evidence regarding whether the polyol-fructokinase pathway directly modulates the risk of
AKI during exercise in humans. This is likely due to a lack of established biomarkers for determining
the activation of these pathways in humans. Further work is required to establish such biomarkers
and to apply this knowledge to exercise in the heat.
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Figure 4. Despite no differences in core temperature or changes in body weight (data not shown),
drinking a high fructose soft drink compared to water during and following 4 h of exercise in the
heat resulted in greater changes (∆) in serum creatinine (A), meeting the criteria for Stage 1 acute
kidney injury (AKI) at Post exercise in ~60% of the subjects (B). During the overnight period (defined
as the time from leaving the laboratory immediately after post-exercise data collection until returning
to the laboratory 24 h following pre-exercise (~18 h following post-exercise)), drinking a soft drink
reduced urine flow rate (despite drinking ~347 mL more fluid during the overnight period) (C) and
elevated urinary neutrophil gelatinase-associated lipocalin (NGAL) (D). These changes in indices in
kidney function and biomarkers of AKI in the soft drink trial were paralleled by greater elevations in
serum uric acid (E) and plasma copeptin (F), a stable surrogate for vasopressin. * different from Water
(p < 0.05), Mean ± SD or individual values, n = 12. F om Chapm n et al. [30] with p mission.
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5. Summary
The purpose of this narrative review was to present evidence that exercise in the heat increases
the risk of developing AKI in humans. A growing body of evidence demonstrates that passive heat
exposure in rodents causes kidney injury, and when this injury is chronically repeated it is capable of
eliciting CKD. Experimental evidence in humans is more limited, with many gaps in the literature
(Table 2). That said, studies consistently demonstrate that a single bout of exercise in the heat increases
biomarkers of AKI and that the magnitude of these elevations in AKI biomarkers is dependent on the
extent of heat strain and dehydration. In this context, elevations in AKI biomarkers are not necessarily
indicative of intrinsic renal damage. Rather, a better interpretation is that they reflect an increased
risk of AKI. Data largely derived from animal models indicate that the mechanism(s) underlying
elevations in AKI biomarkers is multifactorial (Figure 5). For instance, heat-related reductions in renal
blood flow may provoke a heterogenous blood flow distribution within the kidneys. In theory, this
can promote localized ischemia, hypoxemia and ATP depletion, which may be exacerbated by an
increased demand for sodium reabsorption—an energetically expensive process. Moreover, heightened
polyol-fructokinase pathway activity likely exacerbates tissue hypoxemia and ATP depletion, occurring
secondary to the intrarenal production of fructose and hyperuricemia. Collectively, these responses
likely promote inflammation and oxidative stress, which can elevate biomarkers of AKI in otherwise
healthy humans. Unfortunately, there is currently very little direct mechanistic evidence to support
how exercise in the heat may increase the risk of AKI in humans (Table 2). This is an important
knowledge gap that has ramifications regarding the development of countermeasures to safeguard the
renal health of people who regularly engage in physical work in hot environments.
Table 2. Selected identified knowledge gaps regarding the link between exercise in the heat, acute
kidney injury and the development of chronic kidney disease in humans.
• Acute Kidney Injury and the Development of Chronic kidney Disease:
• Can exercise in the heat induce intrinsic renal damage?
• How do we interpret increases in AKI biomarkers associated with exercise in the heat?
• Can repeated exposures to AKI caused by exercise in the heat lead to CKDu? How does the frequency and severity of
this AKI relate to the development and severity of CKDu?
• Does heat acclimation alleviate the risk of AKI (and CKDu) associated with exercise in the heat?
Mechanisms by Which Exercise in the Heat May Increase the Risk Of Acute Kidney Injury:
• What is the relative importance of heat strain versus dehydration on the magnitude of the risk of AKI evoked by
exercise in the heat?
• Do NSAIDs (or other common substances with nephrotoxic side effects) modulate the risk of AKI evoked by exercise
in the heat?
• To what extent does exercise in the heat invoke a heterogenous distribution of blood flow in the kidneys? What are the
contributions of heat strain and/or dehydration?
• Do reductions in renal blood flow during exercise in the heat cause localized ischemia, reductions in oxygenation,
and/or decreases in ATP availability? Where do these changes occur within the kidneys?
• Does exercise in the heat promote inflammation and oxidative stress within the kidneys? What are the contributions of
heat strain and/or dehydration?
• What is the extent by which activation of the Na+/K+ pump contributes to the risk of AKI during exercise in the heat?
• Does the polyol-fructokinase pathway directly contribute to the risk of AKI during exercise in the heat?
• What are the roles of vasopressin and hyperuricemia in the risk of AKI during exercise in the heat?
Abbreviations: AKI: acute kidney injury, CKDu: chronic kidney disease of unknown origins, NSAIDs: nonsteroidal
anti-inflammatory drugs.
Nutrients 2019, 11, 2087 16 of 25
Nutrients 2019, 11, x FOR PEER REVIEW 16 of 25 
 
 
Figure 5. Potential mechanisms by which exercise in the heat and the subsequent development of heat 
strain (i.e., increases in core body temperature) and dehydration (a hypovolemic, hyperosmotic state) 
may increase the risk of acute kidney injury (AKI) while simultaneously promoting fluid 
conservation. Red arrows indicate potential pathophysiological pathways. Blue arrows indicate 
known beneficial physiological responses. Abbreviations—RAAS: Renin–angiotensin–aldosterone 
system, RSNA: Renal sympathetic nerve activity, ATP: adenosine triphosphate. Please refer to text for 
references. 
Author Contributions: Z.J.S., D.H., M.D.P., R.R.P., J.W.L., B.D.J. and C.L.C. conceptualized the manuscript; Z.J.S. 
drafted the manuscript; Z.J.S. prepared figures; Z.J.S., D.H., M.D.P., R.R.P., J.W.L., B.D.J. and C.L.C. edited and 
revised the manuscript; Z.J.S., D.H., M.D.P., R.R.P., J.W.L., B.D.J. and C.L.C. approved the final version of the 
manuscript. 
Funding:  The writing of this manuscript and the work from our laboratory presented herein were not 
externally funded. 
Acknowledgments: We thank the people who participated in the studies described herein. 
Conflicts of interest: The authors have no related conflicts of interest to report. 
References 
1. Chatterjee, R. Occupational hazard. Science 2016, 352, 24–27. 
2. Johnson, R.J.; Wesseling, C.; Newman, L.S. Chronic kidney disease of unknown cause in agricultural 
communities. New Engl. J. Med. 2019, 380, 1843–1852. 
3. Trabanino, R.G.; Aguilar, R.; Silva, C.R.; Mercado, M.O.; Merino, R.L. Nefropatía terminal en pacientes de 
un hospital de referencia en El Salvador. Revista Panamericana de Salud Pública 2002, 12, 202–206. 
4. Torres, C.; Aragón, A.; González, M.; Jakobsson, K.; Elinder, C.-G.; Lundberg, I.; Wesseling, C. Decreased 
kidney function of unknown cause in Nicaragua: A community-based survey. Am. J. Kidney Dis. 2010, 55, 
485–496. 
5. O’Donnell, J.K.; Tobey, M.; Weiner, D.E.; Stevens, L.A.; Johnson, S.; Stringham, P.; Cohen, B.; Brooks, D.R. 
Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrol. Dial. Transplant. 2011, 
26, 2798–2805. 
6. Peraza, S.; Wesseling, C.; Aragon, A.; Leiva, R.; García-Trabanino, R.A.; Torres, C.; Jakobsson, K.; Elinder, 
C.G.; Hogstedt, C. Decreased kidney function among agricultural workers in El Salvador. Am. J. Kidney Dis. 
2012, 59, 531–540. 
7. Glaser, J.; Lemery, J.; Rajagopalan, B.; Diaz, H.F.; García-Trabanino, R.; Taduri, G.; Madero, M.; 
Amarasinghe, M.; Abraham, G.; Anutrakulchai, S. Climate Change and the Emergent Epidemic of CKD 
Fig re 5. Potential echanis s by hich exercise in the heat and the subsequent develop ent of heat
strai (i.e., i creases i c re te erat re) a e y rati (a hypovole ic, hyperos otic state)
increase the risk of acute kidney injur (AKI) while simultaneously promoting fluid c nservation.
Red arrows indicate p tential patho hysiologic l pat ways. Blue arro s indicate known be eficial
physiological response . Abbreviations—RA S: R nin–a giotensin–aldostero e system, RSNA: Re al
mpathetic nerve ctivity, ATP: ad nosine triphosphate. Please refer t text for r ferences.
Author Contributions: Z.J.S., D.H., M.D.P., R.R.P., J.W.L., B.D.J. and C.L.C. conceptualized the manuscript;
Z.J.S. drafted the manuscript; Z.J.S. prepared figures; Z.J.S., D.H., M.D.P., R.R.P., J.W.L., B.D.J. and C.L.C. edited
and revised the manuscript; Z.J.S., D.H., M.D.P., R.R.P., J.W.L., B.D.J. and C.L.C. approved the final version of
the manuscript.
Funding: The writing of this manuscript and the work from our laboratory presented herein were not
externally funded.
Acknowledgments: We thank the people who participated in the studies described herein.
Conflicts of Intere t: The authors have no related conflicts of int rest to report.
References
1. Chatterjee, R. Occupational hazard. Science 2016, 352, 24–27. [CrossRef] [PubMed]
2. Johnson, R.J.; Wesseling, C.; Newman, L.S. Chronic kidney disease of unknown cause in agricultural
communities. New Engl. J. Med. 2019, 380, 1843–1852. [CrossRef] [PubMed]
3. Trabanino, R.G.; Aguilar, R.; Silva, C.R.; Mercado, M.O.; Merino, R.L. Nefropatía terminal en pacientes de un
hospital de referencia en El Salvador. Revista Panamericana de Salud Pública 2002, 12, 202–206. [CrossRef]
[PubMed]
4. Torres, C.; Aragón, A.; González, M.; Jakobsson, K.; Elinder, C.-G.; Lundberg, I.; Wesseling, C. Decreased
kidney function of unknown cause in Nicaragua: A community-based survey. Am. J. Kidney Dis. 2010,
55, 485–496. [CrossRef] [PubMed]
5. O’Donnell, J.K.; Tobey, M.; Weiner, D.E.; Stevens, L.A.; Johnson, S.; Stringham, P.; Cohen, B.; Brooks, D.R.
Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrol. Dial. Transplant. 2011,
26, 2798–2805. [CrossRef] [PubMed]
6. Peraza, S.; Wesseling, C.; Aragon, A.; Leiva, R.; García-Trabanino, R.A.; Torres, C.; Jakobsson, K.; Elinder, C.G.;
Hogstedt, C. Decreased kidney function among agricultural workers in El Salvador. Am. J. Kidney Dis. 2012,
59, 531–540. [CrossRef]
Nutrients 2019, 11, 2087 17 of 25
7. Glaser, J.; Lemery, J.; Rajagopalan, B.; Diaz, H.F.; García-Trabanino, R.; Taduri, G.; Madero, M.;
Amarasinghe, M.; Abraham, G.; Anutrakulchai, S. Climate Change and the Emergent Epidemic of CKD from
Heat Stress in Rural Communities: The Case for Heat Stress Nephropathy. Clin. J. Am. Soc. Nephrol. 2016,
11, 1472–1483. [CrossRef]
8. Flores, S.; Rider, A.C.; Alter, H.J. Mesoamerican nephropathy: A novel case of kidney failure in a US ED.
Am. J. Emerg Med. 2015, 34, 1323.e5–1323.e6. [CrossRef]
9. Organization, P.A.H. Epidemic of Chronic Kidney Disease in Agricultural Communities in Central America
Case Definitions, Methodological Basis and Approaches for Public Health Surveillance; Pan American Health
Organization: Washington, DC, USA, 2017.
10. Elledge, M.F.; Redmon, J.H.; Levine, K.E.; Wickremasinghe, R.J.; Wanigasariya, K.P.; Peiris-John, R.J. Chronic
Kidney Disease of Unknown Etiology in Sri Lanka: Quest for Understanding and Global Implications; RTI Research
Brief. Research; RTI Press: Triangle Park, NC, USA, 2014.
11. Flouris, A.D.; Dinas, P.C.; Ioannou, L.G.; Nybo, L.; Havenith, G.; Kenny, G.P.; Kjellstrom, T. Workers’ health
and productivity under occupational heat strain: A systematic review and meta-analysis. Lancet Planet. Health
2018, 2, e521–e531. [CrossRef]
12. Pearce, N.; Caplin, B. Let’s Take the Heat OUT of the CKDu Debate: More Evidence Is Needed; BMJ Publishing
Group Ltd.: London, UK, 2019.
13. Wijkström, J.; Leiva, R.; Elinder, C.-G.; Leiva, S.; Trujillo, Z.; Trujillo, L.; Söderberg, M.; Hultenby, K.;
Wernerson, A. Clinical and pathological characterization of Mesoamerican nephropathy: A new kidney
disease in Central America. Am. J. Kidney Dis. 2013, 62, 908–918. [CrossRef]
14. Correa-Rotter, R.; Wesseling, C.; Johnson, R.J. CKD of unknown origin in Central America: The case for a
Mesoamerican nephropathy. Am. J. Kidney Dis. 2014, 63, 506–520. [CrossRef] [PubMed]
15. Roncal-Jimenez, C.; Lanaspa, M.; Jensen, T.; Sanchez-Lozada, L.; Johnson, R. Mechanisms by which
dehydration may lead to chronic kidney disease. Ann. Nutr. Metab. 2015, 66, 10–13. [CrossRef] [PubMed]
16. Roncal-Jimenez, C.A.; García-Trabanino, R.; Wesseling, C.; Johnson, R.J. Mesoamerican Nephropathy or
Global Warming Nephropathy? Blood Purif. 2016, 41, 135–138. [CrossRef] [PubMed]
17. Orantes, C.M.; Herrera, R.; Almaguer, M.; Brizuela, E.G.; Hernández, C.E.; Bayarre, H.; Amaya, J.C.;
Calero, D.J.; Orellana, P.; Colindres, R.M. Chronic kidney disease and associated risk factors in the Bajo
Lempa region of El Salvador: Nefrolempa study, 2009. Med. Rev. 2011, 13, 14–22.
18. Herrera, R.; Orantes, C.M.; Almaguer, M.; Alfonso, P.; Bayarre, H.D.; Leiva, I.M.; Smith, M.J.; Cubias, R.A.;
Almendárez, W.O.; Cubias, F.R. Clinical characteristics of chronic kidney disease of nontraditional causes in
Salvadoran farming communities. Med. Rev. 2014, 16, 39–48.
19. Butler-Dawson, J.; Krisher, L.; Asensio, C.; Cruz, A.; Tenney, L.; Weitzenkamp, D.; Dally, M.; Asturias, E.J.;
Newman, L.S. Risk factors for declines in kidney function in sugarcane workers in Guatemala. J. Occup.
Environ. Med. 2018, 60, 548. [CrossRef] [PubMed]
20. González-Quiroz, M.; Pearce, N.; Caplin, B.; Nitsch, D. What do epidemiological studies tell us about
chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis.
Clin. Kidney J. 2017, 11, 496–506. [CrossRef]
21. McClean, M.; Amador, J.J.; Laws, R.; Kaufman, J.S.; Weiner, D.E.; Sanchez-Rodriguez, J.; Brooks, D. Biological
Sampling Report: Investigating Biomarkers of Kidney Injury and Chronic Kidney Disease among Workers in Western
Nicaragua; University School of Public Health; Compliance Advisor Ombudsman: Boston, MA, USA, 2012.
22. Gifford, F.J.; Gifford, R.M.; Eddleston, M.; Dhaun, N. Endemic Nephropathy Across the World. Kidney Int.
2016, 2, 282–292. [CrossRef]
23. Johnson, R.J.; Glaser, J.; Sánchez-Lozada, L.G. Chronic kidney disease of unknown etiology: A disease related
to global warming? Med. Rev. 2014, 16, 79.
24. Chapman, E.; Haby, M.M.; Illanes, E.; Sanchez-Viamonte, J.; Elias, V.; Reveiz, L. Risk factors for chronic kidney
disease of non-traditional causes: A systematic review. Pan Am. J. Pub. Health 2019, 43, e35. [CrossRef]
25. Valcke, M.; Levasseur, M.-E.; da Silva, A.S.; Wesseling, C. Pesticide exposures and chronic kidney disease of
unknown etiology: An epidemiologic review. Environ. Health 2017, 16, 49. [CrossRef] [PubMed]
26. Sorensen, C.J.; Butler-Dawson, J.; Dally, M.; Krisher, L.; Griffin, B.R.; Johnson, R.J.; Lemery, J.; Asensio, C.;
Tenney, L.; Newman, L.S. Risk Factors and Mechanisms Underlying Cross-Shift Decline in Kidney Function
in Guatemalan Sugarcane Workers. J. Occup. Environ. Med. 2019, 61, 239. [CrossRef] [PubMed]
Nutrients 2019, 11, 2087 18 of 25
27. Roncal-Jimenez, C.; García-Trabanino, R.; Barregard, L.; Lanaspa, M.A.; Wesseling, C.; Harra, T.; Aragón, A.;
Grases, F.; Jarquin, E.R.; González, M.A. Heat stress nephropathy from exercise-induced uric acid crystalluria:
A perspective on Mesoamerican nephropathy. Am. J. Kidney Dis. 2016, 67, 20–30. [CrossRef] [PubMed]
28. Madero, M.; García-Arroyo, F.E.; Sánchez-Lozada, L.-G. Pathophysiologic insight into MesoAmerican
nephropathy. Curr. Opin. Nephrol. Hypertens. 2017, 26, 296–302. [CrossRef] [PubMed]
29. Schlader, Z.J.; Chapman, C.L.; Sarkar, S.; Russo, L.; Rideout, T.C.; Parker, M.D.; Johnson, B.D.; Hostler, D.
Firefighter work duration influences the extent of acute kidney injury. Med. Sci. Sport Exerc. 2017,
49, 1745–1753. [CrossRef] [PubMed]
30. Chapman, C.L.; Johnson, B.D.; Sackett, J.R.; Parker, M.D.; Schlader, Z.J. Soft drink consumption during
and following exercise in the heat elevates biomarkers of acute kidney injury. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 2019, 316, R189–R198. [CrossRef]
31. Laws, R.L.; Brooks, D.R.; Amador, J.J.; Weiner, D.E.; Kaufman, J.S.; Ramírez-Rubio, O.; Riefkohl, A.;
Scammell, M.K.; López-Pilarte, D.; Sánchez, J.M. Biomarkers of kidney injury among Nicaraguan sugarcane
workers. Am. J. Kidney Dis. 2016, 67, 209–217. [CrossRef]
32. Butler-Dawson, J.; Krisher, L.; Yoder, H.; Dally, M.; Sorensen, C.; Johnson, R.J.; Asensio, C.; Cruz, A.;
Johnson, E.C.; Carlton, E.J. Evaluation of heat stress and cumulative incidence of acute kidney injury in
sugarcane workers in Guatemala. Int. Arch. Occup. Environ. Health 2019, 1–14. [CrossRef]
33. Au, V.; Feit, J.; Barasch, J.; Sladen, R.N.; Wagener, G. Urinary neutrophil gelatinase–associated lipocalin
(NGAL) distinguishes sustained from transient acute kidney injury after general surgery. Kidney Int. Rep.
2016, 1, 3–9. [CrossRef]
34. Rawson, E.S.; Clarkson, P.M.; Tarnopolsky, M.A. Perspectives on exertional rhabdomyolysis. Sports Med.
2017, 47, 33–49. [CrossRef]
35. Correa-Rotter, R.; García-Trabanino, R. Mesoamerican nephropathy. Semin. Nephrol. 2019, 39, 263–271.
[CrossRef] [PubMed]
36. Junglee, N.A.; Di Felice, U.; Dolci, A.; Fortes, M.B.; Jibani, M.M.; Lemmey, A.B.; Walsh, N.P.; Macdonald, J.H.
Exercising in a hot environment with muscle damage: Effects on acute kidney injury biomarkers and kidney
function. Am. J. Physiol. Ren. Physiol. 2013, 305, F813–F820. [CrossRef] [PubMed]
37. Sánchez-Lozada, L.-G.; García-Arroyo, F.E.; Gonzaga, G.; Silverio, O.; Blas-Marron, M.G.; Muñoz-Jimenez, I.;
Tapia, E.; Osorio-Alonso, H.; Madero, M.; Roncal-Jiménez, C.A. Kidney Injury from Recurrent Heat Stress and
Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate. Am. J. Nephrol. 2018, 48, 339–348.
[CrossRef] [PubMed]
38. Brown, S.J.; Child, R.B.; Day, S.H.; Donnelly, A.E. Exercise-induced skeletal muscle damage and adaptation
following repeated bouts of eccentric muscle contractions. J. Sports Sci. 1997, 15, 215–222. [CrossRef]
[PubMed]
39. Herath, C.; Jayasumana, C.; De Silva, P.M.C.; De Silva, P.C.; Siribaddana, S.; De Broe, M.E. Kidney diseases
in agricultural communities: A case against heat-stress nephropathy. Kidney Int. Rep. 2018, 3, 271–280.
[CrossRef] [PubMed]
40. Basile, D.P.; Bonventre, J.V.; Mehta, R.; Nangaku, M.; Unwin, R.; Rosner, M.H.; Kellum, J.A.; Ronco, C.
Progression after AKI: Understanding maladaptive repair processes to predict and identify therapeutic
treatments. J. Am. Soc. Nephrol. 2015, 27, 687–697. [CrossRef]
41. Basile, D.P.; Anderson, M.D.; Sutton, T.A. Pathophysiology of acute kidney injury. Compr. Physiol. 2011,
2, 1303–1353.
42. Basile, D.P.; Donohoe, D.; Roethe, K.; Osborn, J.L. Renal ischemic injury results in permanent damage to
peritubular capillaries and influences long-term function. Am. J. Physiol. Ren. Physiol. 2001, 281, F887–F899.
[CrossRef]
43. Tanaka, S.; Tanaka, T.; Nangaku, M. Hypoxia as a key player in the AKI-to-CKD transition. Am. J. Physiol.
Ren. Physiol. 2014, 307, F1187–F1195. [CrossRef]
44. Ferenbach, D.A.; Bonventre, J.V. Acute kidney injury and chronic kidney disease: From the laboratory to the
clinic. Nephrol. Ther. 2016, 12, S41–S48. [CrossRef]
45. Humphreys, B.D. Fibrotic Changes Mediating Acute Kidney Injury to Chronic Kidney Disease Transition.
Nephron 2017, 137, 264–267.
Nutrients 2019, 11, 2087 19 of 25
46. Ko, G.J.; Grigoryev, D.N.; Linfert, D.; Jang, H.R.; Watkins, T.; Cheadle, C.; Racusen, L.; Rabb, H. Transcriptional
analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of
AKI-to-CKD transition. Am. J. Physiol. Ren. Physiol. 2010, 298, F1472–F1483. [CrossRef] [PubMed]
47. Roncal-Jimenez, C.A.; Ishimoto, T.; Lanaspa, M.A.; Rivard, C.J.; Nakagawa, T.; Ejaz, A.A.; Cicerchi, C.;
Inaba, S.; Le, M.; Miyazaki, M. Fructokinase activity mediates dehydration-induced renal injury. Kidney Int.
2014, 86, 294–302. [CrossRef] [PubMed]
48. Roncal-Jimenez, C.A.; Milagres, T.; Andres-Hernando, A.; Kuwabara, M.; Jensen, T.; Song, Z.; Bjornstad, P.;
Garcia, G.E.; Sato, Y.; Sanchez-Lozada, L.G. Effects of exogenous desmopressin on a model of heat stress
nephropathy in mice. Am. J. Physiol. Ren. Physiol. 2017, 312, F418–F426. [CrossRef] [PubMed]
49. Roncal-Jimenez, C.A.; Sato, Y.; Milagres, T.; Andres-Hernando, A.; Garcia, G.E.; Bjornstad, P.;
Butler-Dawson, J.; Sorensen, C.; Newman, L.; Krisher, L. Experimental Heat Stress Nephropathy and
Liver Injury are Improved by Allopurinol. Am. J. Physiol. Ren. Physiol. 2018, 315, F726–F733. [CrossRef]
50. Moyce, S.; Joseph, J.; Tancredi, D.; Mitchell, D.; Schenker, M. Cumulative Incidence of Acute Kidney Injury in
California’s Agricultural Workers. J. Occup. Environ. Med. 2016, 58, 391–397. [CrossRef] [PubMed]
51. García-Trabanino, R.; Jarquín, E.; Wesseling, C.; Johnson, R.J.; González-Quiroz, M.; Weiss, I.; Glaser, J.;
Vindell, J.J.; Stockfelt, L.; Roncal, C. Heat stress, dehydration, and kidney function in sugarcane cutters
in El Salvador—A cross-shift study of workers at risk of Mesoamerican nephropathy. Environ. Res. 2015,
142, 746–755. [CrossRef]
52. Laws, R.L.; Brooks, D.R.; Amador, J.J.; Weiner, D.E.; Kaufman, J.S.; Ramírez-Rubio, O.; Riefkohl, A.;
Scammell, M.K.; López-Pilarte, D.; Sánchez, J.M. Changes in kidney function among Nicaraguan sugarcane
workers. Int. J. Occup. Environ. Health 2015, 21, 241–250. [CrossRef]
53. Santos, U.P.; Zanetta, D.M.T.; Terra-Filho, M.; Burdmann, E.A. Burnt sugarcane harvesting is associated with
acute renal dysfunction. Kidney Int. 2015, 87, 792–799. [CrossRef]
54. Wesseling, C.; Aragón, A.; González, M.; Weiss, I.; Glaser, J.; Bobadilla, N.A.; Roncal-Jiménez, C.;
Correa-Rotter, R.; Johnson, R.J.; Barregard, L. Kidney function in sugarcane cutters in Nicaragua–A
longitudinal study of workers at risk of Mesoamerican nephropathy. Environ. Res. 2016, 147, 125–132.
[CrossRef]
55. Moyce, S.; Mitchell, D.; Armitage, T.; Tancredi, D.; Joseph, J.; Schenker, M. Heat strain, volume depletion
and kidney function in California agricultural workers. Occup. Environ. Med. 2017, 74, 402–409. [CrossRef]
[PubMed]
56. Wesseling, C.; García-Trabanino, R.; Wegman, D.H. Mesoamerican Nephropathy: Do Novel Biomarkers of
Kidney Damage Have a Role to Play? Am. J. Kidney Dis. 2016, 67, 173–175. [CrossRef] [PubMed]
57. Heung, M.; Steffick, D.E.; Zivin, K.; Gillespie, B.W.; Banerjee, T.; Hsu, C.-Y.; Powe, N.R.; Pavkov, M.E.;
Williams, D.E.; Saran, R. Acute kidney injury recovery pattern and subsequent risk of CKD: An analysis of
veterans health administration data. Am. J. Kidney Dis. 2016, 67, 742–752. [CrossRef]
58. Coca, S.G.; Singanamala, S.; Parikh, C.R. Chronic kidney disease after acute kidney injury: A systematic
review and meta-analysis. Kidney Int. 2012, 81, 442–448. [CrossRef]
59. Arias-Cabrales, C.; Rodríguez, E.; Bermejo, S.; Sierra, A.; Burballa, C.; Barrios, C.; Soler, M.J.; Pascual, J.
Short-and long-term outcomes after non-severe acute kidney injury. Clin. Exp. Nephrol. 2017, 1–7. [CrossRef]
[PubMed]
60. Ishani, A.; Xue, J.L.; Himmelfarb, J.; Eggers, P.W.; Kimmel, P.L.; Molitoris, B.A.; Collins, A.J. Acute kidney
injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol. 2009, 20, 223–228. [CrossRef]
61. Schiﬄ, H.; Fischer, R. Five-year outcomes of severe acute kidney injury requiring renal replacement therapy.
Nephrol. Dial. Transplant. 2008, 23, 2235–2241. [CrossRef]
62. Uchino, S.; Bellomo, R.; Bagshaw, S.M.; Goldsmith, D. Transient azotaemia is associated with a high risk of
death in hospitalized patients. Nephrol. Dial. Transplant. 2010, 25, 1833–1839. [CrossRef]
63. Chawla, L.S.; Eggers, P.W.; Star, R.A.; Kimmel, P.L. Acute kidney injury and chronic kidney disease as
interconnected syndromes. New Engl. J. Med. 2014, 371, 58–66. [CrossRef]
64. Chawla, L.S.; Kimmel, P.L. Acute kidney injury and chronic kidney disease: An integrated clinical syndrome.
Kidney Int. 2012, 82, 516–524. [CrossRef]
65. Belayev, L.Y.; Palevsky, P.M. The link between AKI and CKD. Curr. Opin. Nephrol. Hypertens. 2014, 23, 149.
[CrossRef] [PubMed]
Nutrients 2019, 11, 2087 20 of 25
66. Roncal, C.A.; Mu, W.; Croker, B.; Reungjui, S.; Ouyang, X.; Tabah-Fisch, I.; Johnson, R.J.; Ejaz, A.A. Effect
of elevated serum uric acid on cisplatin-induced acute renal failure. Am. J. Physiol. Ren. Physiol. 2007,
292, F116–F122. [CrossRef] [PubMed]
67. Ryu, E.-S.; Kim, M.J.; Shin, H.-S.; Jang, Y.-H.; Choi, H.S.; Jo, I.; Johnson, R.J.; Kang, D.-H. Uric acid-induced
phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am. J. Physiol.
Ren. Physiol. 2013, 304, F471–F480. [CrossRef] [PubMed]
68. Suga, S.-I.; Phillips, M.I.; Ray, P.E.; Raleigh, J.A.; Vio, C.P.; Kim, Y.-G.; Mazzali, M.; Gordon, K.L.; Hughes, J.;
Johnson, R.J. Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt
sensitivity. Am. J. Physiol. Ren. Physiol. 2001, 281, F620–F629. [CrossRef] [PubMed]
69. Perner, A.; Prowle, J.; Joannidis, M.; Young, P.; Hjortrup, P.B.; Pettilä, V. Fluid management in acute kidney
injury. Intensive Care Med. 2017, 43, 807–815. [CrossRef] [PubMed]
70. McDermott, B.P.; Smith, C.R.; Butts, C.L.; Caldwell, A.R.; Lee, E.C.; Vingren, J.L.; Munoz, C.X.; Kunces, L.J.;
Williamson, K.; Ganio, M.S. Renal stress and kidney injury biomarkers in response to endurance cycling in
the heat with and without ibuprofen. J. Sci. Med. Sport 2018, 21, 1180–1184. [CrossRef] [PubMed]
71. Kellum, J.A.; Lameire, N.; Aspelin, P.; Barsoum, R.S.; Burdmann, E.A.; Goldstein, S.L.; Herzog, C.A.;
Joannidis, M.; Kribben, A.; Levey, A.S. Kidney disease: Improving global outcomes (KDIGO) acute kidney
injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2012,
2, 1–138.
72. Levey, A.S.; Eckardt, K.-U.; Tsukamoto, Y.; Levin, A.; Coresh, J.; Rossert, J.; Zeeuw, D.D.; Hostetter, T.H.;
Lameire, N.; Eknoyan, G. Definition and classification of chronic kidney disease: A position statement from
Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67, 2089–2100. [CrossRef]
73. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A. Acute Kidney
Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11, R31.
[CrossRef]
74. Bellomo, R.; Ronco, C.; Kellum, J.A.; Mehta, R.L.; Palevsky, P. Acute renal failure–definition, outcome
measures, animal models, fluid therapy and information technology needs: The Second International
Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 2004, 8, R204.
[CrossRef]
75. Kellum, J.A.; Lameire, N. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary
(Part 1). Crit. Care 2013, 17, 204. [CrossRef] [PubMed]
76. Beierwaltes, W.H.; Harrison-Bernard, L.M.; Sullivan, J.C.; Mattson, D.L. Assessment of renal function;
clearance, the renal microcirculation, renal blood flow, and metabolic balance. Compr. Physiol. 2013,
3, 165–200. [PubMed]
77. Traynor, J.; Mactier, R.; Geddes, C.C.; Fox, J.G. How to measure renal function in clinical practice. BMJ 2006,
333, 733–737. [CrossRef] [PubMed]
78. Yong, Z.; Pei, X.; Zhu, B.; Yuan, H.; Zhao, W. Predictive value of serum cystatin C for acute kidney injury in
adults: A meta-analysis of prospective cohort trials. Sci. Rep. 2017, 7, 41012. [CrossRef] [PubMed]
79. Odutayo, A.; Cherney, D. Cystatin C and acute changes in glomerular filtration rate. Clin. Nephrol. 2012,
78, 64–75. [CrossRef] [PubMed]
80. Parikh, C.R.; Coca, S.G. Acute kidney injury: Defining prerenal azotemia in clinical practice and research.
Nat. Rev. Nephrol. 2010, 6, 641. [CrossRef]
81. McCance, R.; Widdowson, E. The secretion of urine in man during experimental salt deficiency. J. Physiol.
1937, 91, 222–231. [CrossRef]
82. Nadal, J.W.; Pedersen, S.; Maddock, W.G. A comparison between dehydration from salt loss and from water
deprivation. J. Clin. Invest. 1941, 20, 691. [CrossRef]
83. Kirkebø, A.; Tyssebotn, I. Effect of dehydration on renal blood flow in dog. Acta Physiol. Scand. 1977,
101, 257–263. [CrossRef]
84. Hope, A.; Tyssebotn, I. The effect of water deprivation on local renal blood flow and filtration in the laboratory
rat. Circ. Shock 1982, 11, 175–186.
85. Stocker, S.D.; Hunwick, K.J.; Toney, G.M. Hypothalamic paraventricular nucleus differentially supports
lumbar and renal sympathetic outflow in water-deprived rats. J. Physiol. 2005, 563, 249–263. [CrossRef]
[PubMed]
Nutrients 2019, 11, 2087 21 of 25
86. Bardgett, M.E.; Chen, Q.-H.; Guo, Q.; Calderon, A.S.; Andrade, M.A.; Toney, G.M. Coping with dehydration:
Sympathetic activation and regulation of glutamatergic transmission in the hypothalamic PVN. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 2014, 306, R804–R813. [CrossRef] [PubMed]
87. Bie, P. Osmoreceptors, vasopressin, and control of renal water excretion. Physiol. Rev. 1980, 60, 961–1048.
[CrossRef] [PubMed]
88. Di Nicolantonio, R.; Mendelsohn, F. Plasma renin and angiotensin in dehydrated and rehydrated rats. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 1986, 250, R898–R901. [CrossRef] [PubMed]
89. Mack, G.W.; Nadel, E.R. Body fluid balance during heat stress in humans. In Comprehensive Physiology;
Supplement 14: Handbook of Physiology, Environmental Physiology; Wiley: Hoboken, NJ, USA, 2011;
pp. 187–214.
90. Cheuvront, S.N.; Ely, B.R.; Kenefick, R.W.; Sawka, M.N. Biological variation and diagnostic accuracy of
dehydration assessment markers. Am. J. Clin. Nutr. 2010, 92, 565–573. [CrossRef]
91. Griffin, B.R.; Gist, K.M.; Faubel, S. Current status of novel biomarkers for the diagnosis of acute kidney
injury: A historical perspective. J. Intensive Care Med. 2019, 0885066618824531. [CrossRef] [PubMed]
92. Malhotra, R.; Siew, E.D. Biomarkers for the early detection and prognosis of acute kidney injury. Clin. J. Am.
Soc. Nephrol. 2017, 12, 149–173. [CrossRef]
93. Koyner, J.L.; Parikh, C.R. Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin. J.
Am. Soc. Nephrol. 2013, 8, 1034–1042. [CrossRef]
94. Schrezenmeier, E.; Barasch, J.; Budde, K.; Westhoff, T.; Schmidt-Ott, K. Biomarkers in acute kidney
injury–pathophysiological basis and clinical performance. Acta Physiol. 2017, 219, 556–574. [CrossRef]
95. Schaub, J.A.; Parikh, C.R. Biomarkers of acute kidney injury and associations with short-and long-term
outcomes. F1000Research 2016, 5. [CrossRef]
96. Kashani, K.; Kellum, J.A. Novel biomarkers indicating repair or progression after acute kidney injury.
Curr. Opin. Nephrol. Hypertens. 2015, 24, 21–27. [CrossRef] [PubMed]
97. Haase, M.; Kellum, J.A.; Ronco, C. Subclinical AKI—An emerging syndrome with important consequences.
Nat. Rev. Nephrol. 2012, 8, 735. [CrossRef] [PubMed]
98. Chakraborty, S.; Kaur, S.; Guha, S.; Batra, S.K. The multifaceted roles of neutrophil gelatinase associated
lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta Rev. Cancer 2012, 1826, 129–169.
[CrossRef] [PubMed]
99. Goetz, D.H.; Holmes, M.A.; Borregaard, N.; Bluhm, M.E.; Raymond, K.N.; Strong, R.K. The neutrophil
lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell
2002, 10, 1033–1043. [CrossRef]
100. Mishra, J.; Mori, K.; Ma, Q.; Kelly, C.; Barasch, J.; Devarajan, P. Neutrophil gelatinase-associated lipocalin: A
novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 2004, 24, 307–315. [CrossRef]
101. Mishra, J.; Dent, C.; Tarabishi, R.; Mitsnefes, M.M.; Ma, Q.; Kelly, C.; Ruff, S.M.; Zahedi, K.; Shao, M.; Bean, J.
Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.
Lancet 2005, 365, 1231–1238. [CrossRef]
102. Mishra, J.; Ma, Q.; Prada, A.; Mitsnefes, M.; Zahedi, K.; Yang, J.; Barasch, J.; Devarajan, P. Identification of
neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am.
Soc. Nephrol. 2003, 14, 2534–2543. [CrossRef]
103. Supavekin, S.; Zhang, W.; Kucherlapati, R.; Kaskel, F.J.; Moore, L.C.; Devarajan, P. Differential gene expression
following early renal ischemia/reperfusion. Kidney Int. 2003, 63, 1714–1724. [CrossRef]
104. Schmidt-Ott, K.M.; Mori, K.; Li, J.Y.; Kalandadze, A.; Cohen, D.J.; Devarajan, P.; Barasch, J. Dual action of
neutrophil gelatinase–associated lipocalin. J. Am. Soc. Nephrol. 2007, 18, 407–413. [CrossRef]
105. Hvidberg, V.; Jacobsen, C.; Strong, R.K.; Cowland, J.B.; Moestrup, S.K.; Borregaard, N. The endocytic
receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity
and mediates its cellular uptake. FEBS Lett. 2005, 579, 773–777. [CrossRef]
106. Singer, E.; Elger, A.; Elitok, S.; Kettritz, R.; Nickolas, T.L.; Barasch, J.; Luft, F.C.; Schmidt-Ott, K.M. Urinary
neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts
outcomes. Kidney Int. 2011, 80, 405–414. [CrossRef] [PubMed]
107. Nejat, M.; Pickering, J.W.; Devarajan, P.; Bonventre, J.V.; Edelstein, C.L.; Walker, R.J.; Endre, Z.H. Some
biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int. 2012, 81, 1254–1262.
[CrossRef] [PubMed]
Nutrients 2019, 11, 2087 22 of 25
108. Ichimura, T.; Bonventre, J.V.; Bailly, V.; Wei, H.; Hession, C.A.; Cate, R.L.; Sanicola, M. Kidney injury
molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain,
is up-regulated in renal cells after injury. J. Biol. Chem. 1998, 273, 4135–4142. [CrossRef] [PubMed]
109. Prozialeck, W.; Vaidya, V.; Liu, J.; Waalkes, M.; Edwards, J.; Lamar, P.; Bernard, A.; Dumont, X.; Bonventre, J.
Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int. 2007, 72, 985–993.
[CrossRef] [PubMed]
110. Ichimura, T.; Hung, C.C.; Yang, S.A.; Stevens, J.L.; Bonventre, J.V. Kidney injury molecule-1: A tissue and
urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Ren. Physiol. 2004, 286, F552–F563.
[CrossRef]
111. Han, W.K.; Bailly, V.; Abichandani, R.; Thadhani, R.; Bonventre, J.V. Kidney Injury Molecule-1 (KIM-1): A
novel biomarker for human renal proximal tubule injury. Kidney Int. 2002, 62, 237–244. [CrossRef] [PubMed]
112. Wang, G.; Gong, Y.; Anderson, J.; Sun, D.; Minuk, G.; Roberts, M.S.; Burczynski, F.J. Antioxidative function
of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology 2005, 42, 871–879. [CrossRef]
113. Yamamoto, T.; Noiri, E.; Ono, Y.; Doi, K.; Negishi, K.; Kamijo, A.; Kimura, K.; Fujita, T.; Kinukawa, T.;
Taniguchi, H. Renal L-type fatty acid–binding protein in acute ischemic injury. J. Am. Soc. Nephrol. 2007,
18, 2894–2902. [CrossRef]
114. Doi, K.; Negishi, K.; Ishizu, T.; Katagiri, D.; Fujita, T.; Matsubara, T.; Yahagi, N.; Sugaya, T.; Noiri, E.
Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit. Care Med. 2011,
39, 2464–2469. [CrossRef]
115. Gauer, S.; Sichler, O.; Obermüller, N.; Holzmann, Y.; Kiss, E.; Sobkowiak, E.; Pfeilschifter, J.; Geiger, H.;
Mühl, H.; Hauser, I. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007, 72, 1081–1087.
[CrossRef]
116. Franke, E.I.; Vanderbrink, B.A.; Hile, K.L.; Zhang, H.; Cain, A.; Matsui, F.; Meldrum, K.K. Renal IL-18
production is macrophage independent during obstructive injury. PLoS ONE 2012, 7, e47417. [CrossRef]
[PubMed]
117. Lin, X.; Yuan, J.; Zhao, Y.; Zha, Y. Urine interleukin-18 in prediction of acute kidney injury: A systemic review
and meta-analysis. J. Nephrol. 2015, 28, 7–16. [CrossRef]
118. Kellum, J.A.; Chawla, L.S. Cell-cycle arrest and acute kidney injury: The light and the dark sides.
Nephrol. Dial. Transplant. 2015, 31, 16–22. [CrossRef] [PubMed]
119. Rodier, F.; Campisi, J.; Bhaumik, D. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res. 2007,
35, 7475–7484. [CrossRef] [PubMed]
120. Shankland, S.J. Cell cycle regulatory proteins in glomerular disease. Kidney Int. 1999, 56, 1208–1215.
[CrossRef] [PubMed]
121. Witzgall, R.; Brown, D.; Schwarz, C.; Bonventre, J.V. Localization of proliferating cell nuclear antigen,
vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response
among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J. Clin. Investig.
1994, 93, 2175–2188. [CrossRef] [PubMed]
122. Yang, L.; Besschetnova, T.Y.; Brooks, C.R.; Shah, J.V.; Bonventre, J.V. Epithelial cell cycle arrest in G2/M
mediates kidney fibrosis after injury. Nat. Med. 2010, 16, 535. [CrossRef]
123. Kashani, K.; Al-Khafaji, A.; Ardiles, T.; Artigas, A.; Bagshaw, S.M.; Bell, M.; Bihorac, A.; Birkhahn, R.;
Cely, C.M.; Chawla, L.S. Discovery and validation of cell cycle arrest biomarkers in human acute kidney
injury. Crit. Care 2013, 17, R25. [CrossRef]
124. Endre, Z.H.; Pickering, J.W. Acute kidney injury: Cell cycle arrest biomarkers win race for AKI diagnosis.
Nat. Rev. Nephrol. 2014, 10, 683. [CrossRef]
125. Price, P.M.; Safirstein, R.L.; Megyesi, J. The cell cycle and acute kidney injury. Kidney Int. 2009, 76, 604–613.
[CrossRef]
126. Johnson, A.C.; Zager, R.A. Mechanisms Underlying Increased TIMP2 and IGFBP7 Urinary Excretion in
Experimental AKI. J. Am. Soc. Nephrol. 2018, 76, 604–613. [CrossRef] [PubMed]
127. McCullough, P.A.; Chinnaiyan, K.M.; Gallagher, M.J.; Colar, J.M.; Geddes, T.; Gold, J.M.; Trivax, J.E. Changes
in renal markers and acute kidney injury after marathon running. Nephrology 2011, 16, 194–199. [CrossRef]
[PubMed]
Nutrients 2019, 11, 2087 23 of 25
128. Hoffman, M.D.; Stuempfle, K.J.; Fogard, K.; Hew-Butler, T.; Winger, J.; Weiss, R.H. Urine dipstick analysis for
identification of runners susceptible to acute kidney injury following an ultramarathon. J. Sport Sci. 2013,
31, 20–31. [CrossRef] [PubMed]
129. Hou, S.-K.; Chiu, Y.-H.; Tsai, Y.-F.; Tai, L.-C.; Hou, P.C.; How, C.-K.; Yang, C.-C.; Kao, W.-F. Clinical impact
of speed variability to identify ultramarathon runners at risk for acute kidney injury. PLoS ONE 2015,
10, e0133146. [CrossRef] [PubMed]
130. Mansour, S.G.; Verma, G.; Pata, R.W.; Martin, T.G.; Perazella, M.A.; Parikh, C.R. Kidney injury and repair
biomarkers in marathon runners. Am. J. Kidney Dis. 2017, 70, 252–261. [CrossRef] [PubMed]
131. Bongers, C.C.; Alsady, M.; Nijenhuis, T.; Hartman, Y.A.; Eijsvogels, T.M.; Deen, P.M.; Hopman, M.T. Impact
of acute versus repetitive moderate intensity endurance exercise on kidney injury markers. Physiol. Rep.
2017, 5, e13544. [CrossRef] [PubMed]
132. Bongers, C.C.; Alsady, M.; Nijenhuis, T.; Tulp, A.D.; Eijsvogels, T.M.; Deen, P.M.; Hopman, M.T. Impact of
acute versus prolonged exercise and dehydration on kidney function and injury. Physiol. Rep. 2018, 6, e13734.
[CrossRef] [PubMed]
133. Eichner, E.R. Is Heat Stress Nephropathy a Concern for Endurance Athletes? Curr. Sport Med. Rep. 2017,
16, 299–300. [CrossRef]
134. Latham, A. The history of a habit: Jogging as a palliative to sedentariness in 1960s America. Cult. Geogr.
2015, 22, 103–126. [CrossRef]
135. Rewa, O.; Bagshaw, S.M. Acute kidney injury—Epidemiology, outcomes and economics. Nat. Rev. Nephrol.
2014, 10, 193. [CrossRef]
136. Stump, C.S. Physical activity in the prevention of chronic kidney disease. Cardiorenal Med. 2011, 1, 164–173.
[CrossRef] [PubMed]
137. Murray, P.T.; Mehta, R.L.; Shaw, A.; Ronco, C.; Endre, Z.; Kellum, J.A.; Chawla, L.S.; Cruz, D.; Ince, C.;
Okusa, M.D. Potential use of biomarkers in acute kidney injury: Report and summary of recommendations
from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 2014, 85, 513–521. [CrossRef]
[PubMed]
138. Katz, N.; Ronco, C. Acute kidney stress—A useful term based on evolution in the understanding of acute
kidney injury. Crit. Care 2015, 20, 23. [CrossRef] [PubMed]
139. Kellum, J.A. Diagnostic criteria for acute kidney injury: Present and future. Crit. Care Clin. 2015, 31, 621–632.
[CrossRef] [PubMed]
140. Waikar, S.S.; Sabbisetti, V.S.; Bonventre, J.V. Normalization of urinary biomarkers to creatinine during
changes in glomerular filtration rate. Kidney Int. 2010, 78, 486–494. [CrossRef]
141. Junglee, N.A.; Lemmey, A.B.; Burton, M.; Searell, C.; Jones, D.; Lawley, J.S.; Jibani, M.M.; Macdonald, J.H.
Does proteinuria-inducing physical activity increase biomarkers of acute kidney injury? Kidney Blood
Press. Res. 2012, 36, 278–289. [CrossRef]
142. Schrier, R.W.; Henderson, H.S.; Tisher, C.C.; Tannen, R.L. Nephropathy associated with heat stress and
exercise. Ann. Intern. Med. 1967, 67, 356–376. [CrossRef]
143. Schrier, R.W.; Hano, J.; Keller, H.I.; Finkel, R.M.; Gilliland, P.F.; Cirksena, W.J.; Teschan, P.E. Renal, metabolic,
and circulatory responses to heat and exercise. Studies in military recruits during summer training, with
implications for acute renal failure. Ann. Intern. Med. 1970, 73, 213–223. [CrossRef]
144. Montain, S.J.; Coyle, E.F. Influence of graded dehydration on hyperthermia and cardiovascular drift during
exercise. J. Appl. Physiol. 1992, 73, 1340–1350. [CrossRef]
145. Farquhar, W.; Morgan, A.; Zambraski, E.; Kenney, W. Effects of acetaminophen and ibuprofen on renal
function in the stressed kidney. J. Appl. Physiol. 1999, 86, 598–604. [CrossRef]
146. Radigan, L.R.; Robinson, S. Effects of environmental heat stress and exercise on renal blood flow and filtration
rate. J. Appl. Physiol. 1949, 2, 185–191. [CrossRef] [PubMed]
147. Barclay, J.; Cooke, W.; Kenney, R.; Nutt, M.E. The effects of water diuresis and exercise on the volume and
composition of the urine. Am. J. Physiol. 1947, 148, 327–337. [CrossRef] [PubMed]
148. Kenney, W.; Zappe, D. Effect of age on renal blood flow during exercise. Aging Clin. Exp. Res. 1994, 6, 293–302.
[CrossRef]
149. Kawakami, S.; Yasuno, T.; Matsuda, T.; Fujimi, K.; Ito, A.; Yoshimura, S.; Uehara, Y.; Tanaka, H.; Saito, T.;
Higaki, Y. Association between exercise intensity and renal blood flow evaluated using ultrasound echo.
Clin. Exp. Nephrol. 2018, 22, 1061–1068. [CrossRef] [PubMed]
Nutrients 2019, 11, 2087 24 of 25
150. Smith, J.; Robinson, S.; Pearcy, M. Renal responses to exercise, heat and dehydration. J. Appl. Physiol. 1952,
4, 659–665. [CrossRef] [PubMed]
151. Wilson, T.E. Renal sympathetic nerve, blood flow, and epithelial transport responses to thermal stress.
Auton. Neurosci. Basic Clin. 2017, 204, 25–34. [CrossRef] [PubMed]
152. Azzawi, S.; Shirley, D. The effect of vasopressin on renal blood flow and its distribution in the rat. J. Physiol.
1983, 341, 233–244. [CrossRef] [PubMed]
153. Freeman, R.H.; Davis, J.O.; Vitale, S.J.; Johnson, J.A. Intrarenal role of angiotensin II: Homeostatic regulation
of renal blood flow in the dog. Circ. Res. 1973, 32, 692–698. [CrossRef] [PubMed]
154. Mittleman, K.D. Influence of angiotensin II blockade during exercise in the heat. Eur. J. Appl. Physiol.
Occup. Physiol. 1996, 72, 542–547. [CrossRef]
155. Miyamoto, M. Renal cortical and medullary tissue blood flow during experimental hyperthermia in dogs.
Therm. Med 1994, 10, 78–89. [CrossRef]
156. Devarajan, P. Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol. 2006, 17, 1503–1520.
[CrossRef] [PubMed]
157. Zhuo, J.L.; Li, X.C. Proximal nephron. Compr. Physiol. 2013, 3, 1079–1123. [CrossRef] [PubMed]
158. Palmer, L.G.; Schnermann, J. Integrated control of Na transport along the nephron. Clin. J. Am. Soc. Nephrol.
2015, 10, 676–687. [CrossRef] [PubMed]
159. El Mernissi, G.; Doucet, A. Short-term effect of aldosterone on renal sodium transport and tubular
Na−K-ATPase in the rat. Pflügers Arch. 1983, 399, 139–146. [CrossRef]
160. Johnson, M.D.; Malvin, R.L. Stimulation of renal sodium reabsorption by angiotensin II. Am. J. Physiol.
Ren. Physiol. 1977, 232, F298–F306. [CrossRef]
161. Bell-Reuss, E.; Trevino, D.; Gottschalk, C. Effect of renal sympathetic nerve stimulation on proximal water
and sodium reabsorption. J. Clin. Investig. 1976, 57, 1104–1107. [CrossRef]
162. Montain, S.J.; Laird, J.E.; Latzka, W.A.; Sawka, M.N. Aldosterone and vasopressin responses in the heat:
Hydration level and exercise intensity effects. Med. Sci. Sports Exerc. 1997, 29, 661–668. [CrossRef]
163. Kenney, M.J.; Barney, C.C.; Hirai, T.; Gisolfi, C.V. Sympathetic nerve responses to hyperthermia in the
anesthetized rat. J. Appl. Physiol. 1995, 78, 881–889. [CrossRef]
164. Melin, B.; Koulmann, N.; Jimenez, C.; Savourey, G.; Launay, J.-C.; Cottet-Emard, J.-M.; Pequignot, J.-M.;
Allevard, A.-M.; Gharib, C. Comparison of passive heat or exercise-induced dehydration on renal water and
electrolyte excretion: The hormonal involvement. Eur. J. Appl. Physiol. 2001, 85, 250–258. [CrossRef]
165. Doucet, A. Function and control of Na-K-ATPase in single nephron segments of the mammalian kidney.
Kidney Int. 1988, 34, 749–760. [CrossRef]
166. Barrera-Chimal, J.; Pérez-Villalva, R.; Ortega, J.A.; Sánchez, A.; Rodríguez-Romo, R.; Durand, M.; Jaisser, F.;
Bobadilla, N.A. Mild ischemic injury leads to long-term alterations in the kidney: Amelioration by
spironolactone administration. Int. J. Biol. Sci. 2015, 11, 892. [CrossRef] [PubMed]
167. Lattenist, L.; Lechner, S.M.; Messaoudi, S.; Le Mercier, A.; El Moghrabi, S.; Prince, S.; Bobadilla, N.A.;
Kolkhof, P.; Jaisser, F.; Barrera-Chimal, J. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Protects Against Acute Kidney Injury–Mediated Chronic Kidney Disease: Role of Oxidative Stress.
Hypertension 2017, 69, 870–878. [CrossRef] [PubMed]
168. Otani, H.; Kaya, M.; Tsujita, J. Effect of the volume of fluid ingested on urine concentrating ability during
prolonged heavy exercise in a hot environment. J. Sports Sci. Med. 2013, 12, 197. [PubMed]
169. Evans, R.G.; Ince, C.; Joles, J.A.; Smith, D.W.; May, C.N.; O’Connor, P.M.; Gardiner, B.S. Haemodynamic
influences on kidney oxygenation: Clinical implications of integrative physiology. Clin. Exp.
Pharmacol. Physiol. 2013, 40, 106–122. [CrossRef] [PubMed]
170. Chayoth, R.; Kleinman, D.; Kaplanski, J.; Sod Moriah, U. Renal clearance of urea, inulin, and p-aminohippurate
in heat-acclimated rats. J. Appl. Physiol. 1984, 57, 731–732. [CrossRef] [PubMed]
171. Taylor, N.A. Human heat adaptation. Compr. Physiol. 2014, 4, 325–365. [PubMed]
172. Omassoli, J.; Hill, N.E.; Woods, D.R.; Delves, S.K.; Fallowfield, J.L.; Brett, S.J.; Wilson, D.; Corbett, R.W.;
Allsopp, A.J.; Stacey, M.J. Variation in renal responses to exercise in the heat with progressive acclimatisation.
J. Sci. Med. Sport 2019, 22, 1004–1009. [CrossRef] [PubMed]
173. Ho, C.W.; Beard, J.L.; Farrell, P.A.; Minson, C.T.; Kenney, W.L. Age, fitness, and regional blood flow during
exercise in the heat. J. Appl. Physiol. 1997, 82, 1126–1135. [CrossRef]
Nutrients 2019, 11, 2087 25 of 25
174. Minson, C.T.; Wladkowski, S.L.; Cardell, A.F.; Pawelczyk, J.A.; Kenney, W.L. Age alters the cardiovascular
response to direct passive heating. J. Appl. Physiol. 1998, 84, 1323–1332. [CrossRef]
175. Lim, Y.-H.; So, R.; Lee, C.; Hong, Y.-C.; Park, M.; Kim, L.; Yoon, H.-J. Ambient temperature and hospital
admissions for acute kidney injury: A time-series analysis. Sci. Total Environ. 2018, 616, 1134–1138. [CrossRef]
176. McTavish, R.K.; Richard, L.; McArthur, E.; Shariff, S.Z.; Acedillo, R.; Parikh, C.R.; Wald, R.; Wilk, P.; Garg, A.X.
Association between high environmental heat and risk of acute kidney injury among older adults in a
northern climate: A matched case-control study. Am. J. Kidney Dis. 2018, 71, 200–208. [CrossRef] [PubMed]
177. Kim, E.; Kim, H.; Kim, Y.C.; Lee, J.P. Association between extreme temperature and kidney disease in South
Korea, 2003–2013: Stratified by sex and age groups. Sci. Total Environ. 2018, 642, 800–808. [CrossRef]
[PubMed]
178. Bobb, J.F.; Obermeyer, Z.; Wang, Y.; Dominici, F. Cause-specific risk of hospital admission related to extreme
heat in older adults. JAMA 2014, 312, 2659–2667. [CrossRef] [PubMed]
179. Roncal-Jimenez, C.A.; Ishimoto, T.; Lanaspa, M.A.; Milagres, T.; Hernando, A.A.; Jensen, T.; Miyazaki, M.;
Doke, T.; Hayasaki, T.; Nakagawa, T. Aging-associated renal disease in mice is fructokinase dependent. Am. J.
Physiol. Ren. Physiol. 2016, 311, F722–F730. [CrossRef] [PubMed]
180. Stachenfeld, N.S.; Mack, G.W.; Takamata, A.; DiPietro, L.; Nadel, E.R. Thirst and fluid regulatory responses to
hypertonicity in older adults. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1996, 271, R757–R765. [CrossRef]
181. Phillips, P.A.; Rolls, B.J.; Ledingham, J.G.; Forsling, M.L.; Morton, J.J.; Crowe, M.J.; Wollner, L. Reduced thirst
after water deprivation in healthy elderly men. New Engl. J. Med. 1984, 311, 753–759. [CrossRef]
182. Garcia-Arroyo, F.E.; Cristóbal, M.; Arellano-Buendía, A.S.; Osorio, H.; Tapia, E.; Soto, V.; Madero, M.;
Lanaspa, M.A.; Roncal-Jimenez, C.A.; Bankir, L. Rehydration with Soft Drink-like Beverages Exacerbates
Dehydration and Worsens Dehydration-associated Renal Injury. Am. J. Physiol. Regul. Integr. Comp. Physiol.
2016, 111, R57–R65. [CrossRef]
183. García-Arroyo, F.E.; Tapia, E.; Blas-Marron, M.G.; Gonzaga, G.; Silverio, O.; Cristóbal, M.; Osorio, H.;
Arellano-Buendía, A.S.; Zazueta, C.; Aparicio-Trejo, O.E. Vasopressin Mediates the Renal Damage Induced by
Limited Fructose Rehydration in Recurrently Dehydrated Rats. Int. J. Biol. Sci. 2017, 13, 961–975. [CrossRef]
184. Burg, M.B. Molecular basis of osmotic regulation. Am. J. Physiol. Ren. Physiol. 1995, 268, F983–F996.
[CrossRef]
185. Johnson, R.J.; Rodriguez-Iturbe, B.; Roncal-Jimenez, C.; Lanaspa, M.A.; Ishimoto, T.; Nakagawa, T.;
Correa-Rotter, R.; Wesseling, C.; Bankir, L.; Sanchez-Lozada, L.G. Hyperosmolarity drives hypertension and
CKD–water and salt revisited. Nat. Rev. Nephrol. 2014, 10, 415–420. [CrossRef]
186. Cirillo, P.; Gersch, M.S.; Mu, W.; Scherer, P.M.; Kim, K.M.; Gesualdo, L.; Henderson, G.N.; Johnson, R.J.;
Sautin, Y.Y. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in
proximal tubular cells. J. Am. Soc. Nephrol. 2009, 20, 545–553. [CrossRef] [PubMed]
187. Lanaspa, M.A.; Ishimoto, T.; Cicerchi, C.; Tamura, Y.; Roncal-Jimenez, C.A.; Chen, W.; Tanabe, K.;
Andres-Hernando, A.; Orlicky, D.J.; Finol, E. Endogenous fructose production and fructokinase activation
mediate renal injury in diabetic nephropathy. J. Am. Soc. Nephrol. 2014, 25, 2526–2538. [CrossRef] [PubMed]
188. Sanchez-Lozada, L.G.; Tapia, E.; Santamaria, J.; Avila-Casado, C.; Soto, V.; Nepomuceno, T.;
Rodriguez-Iturbe, B.; Johnson, R.J.; Herrera-Acosta, J. Mild hyperuricemia induces vasoconstriction and
maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005, 67, 237–247.
[CrossRef] [PubMed]
189. Huang, Z.; Hong, Q.; Zhang, X.; Xiao, W.; Wang, L.; Cui, S.; Feng, Z.; Lv, Y.; Cai, G.; Chen, X. Aldose reductase
mediates endothelial cell dysfunction induced by high uric acid concentrations. Cell Commun. Signal. 2017,
15, 3. [CrossRef] [PubMed]
190. Song, Z.; Roncal-Jimenez, C.A.; Lanaspa-Garcia, M.A.; Oppelt, S.A.; Kuwabara, M.; Jensen, T.; Milagres, T.;
Andres-Hernando, A.; Ishimoto, T.; Garcia, G.E. Role of fructose and fructokinase in acute dehydration-induced
vasopressin gene expression and secretion in mice. J. Neurophysiol. 2016, 117, 646–654. [CrossRef] [PubMed]
191. Schrier, R.; Berl, T.; Anderson, R. Osmotic and nonosmotic control of vasopressin release. Am. J. Physiol.
Ren. Physiol. 1979, 236, F321–F332. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
